If you lift and take a GLP-1 medication, you can work to keep your strength and muscle while the fat comes off. The plan is to eat protein-rich meals you can tolerate, keep resistance training going at a level your symptoms allow, and stay in regular contact with the clinician who prescribes the drug. This guide gives you meal templates for low-appetite and normal days, a training structure built around a few anchor lifts, and a weekly check of weight, waist, lifts and food.
Say your squat stalled three weeks ago. Your bench is trending down. The scale is dropping fast, people are complimenting the weight loss, and your appetite is so quiet that you forgot to eat lunch twice this week. The medication is doing what it was prescribed to do. These are signs to adjust the plan, and none of them means you did something wrong. Low appetite can pull protein intake, meal size and session quality down without hunger to flag it.
Trials show that GLP-1 weight loss includes some lean mass along with fat. How much varies a lot between studies and between people, and trained men were rarely studied. Lean mass is also broader than muscle, and some trials found strength and function held steady or improved. Protein and resistance training are two of the factors you can plan, so they are worth setting up early.
Much of the GLP-1 research and advice centers on adults who were not training. For a man who already lifts, the general advice to eat protein and lift weights is right, and this guide adds the specifics. That means a protein target tied to body weight and training status, meal templates for low-appetite days, a rate-of-loss guide, a training program that can scale down when symptoms flare, and a weekly review of a few signals. Most of these numbers come from general sports-nutrition research in people not taking these drugs. They are practical estimates, and no trial has tested them as one system on semaglutide, tirzepatide or retatrutide. Retatrutide is an investigational drug with no regulatory approval, so this guide does not treat it as a routine alternative to the approved medications.
If you are still sorting through the broader peptide landscape and need to separate GLP-1 receptor agonists from growth hormone secretagogues, collagen supplements, and research-only compounds, start with Peptides for Body Recomposition as the evidence and decision framework. If you need the foundational nutrition setup for GLP-1 therapy before the training-specific playbook, read the GLP-1 diet guide. If your real question is how the semaglutide brands split in practice, use Ozempic and Wegovy: Training and Nutrition Plan for Lifters for the brand-specific meal-tolerance and titration-week setup.
01Why GLP-1 recomposition can go wrong for lifters
How under-eating can go unnoticed
For lifters, the practical concern with GLP-1 medications is that they can make under-eating feel comfortable instead of alarming.
In a normal calorie deficit, under-eating often comes with clear warning signals. Hunger climbs. Energy drops. Food thoughts get louder. On a GLP-1 medication, those signals can quiet down. Some people eat 1,200 calories for weeks and feel fine. You can skip a meal and not notice. You can walk into the gym after two low-protein days and only realize something is off when the bar feels twenty pounds heavier than it should.
The risk is a gradual slide where the scale moves, the compliments come in, and your training log and food log give the clearest early signals.
Lean-mass loss in trials
Lean-mass loss during weight loss is not unique to GLP-1 therapy. It is common in calorie deficits, after bariatric surgery, and in drug-assisted weight-loss trials, and the amount varies a lot between people and studies. The useful questions are how much of the loss is lean tissue and whether strength and function hold up.
In the STEP 1 trial, adults with overweight or obesity without diabetes received semaglutide 2.4 mg weekly or placebo alongside a lifestyle intervention. At 68 weeks, the semaglutide group achieved a mean weight loss of 14.9 percent compared to 2.4 percent with placebo. The body-composition sub-analysis showed that semaglutide reduced fat mass by approximately 8.4 kg and lean mass by approximately 5.3 kg.1 That lean-mass number is the one that concerns lifters. It is also the number that changes meaning with context, because the trial population was not resistance-trained and the lifestyle intervention did not include a structured progressive-overload program.
A 2025 systematic review and network meta-analysis in Metabolism summarizing 22 randomized trials and 2,258 participants estimated that about 25 percent of total weight loss on obesity medications including semaglutide and tirzepatide was attributable to lean tissue.2 A 2024 review in Diabetes, Obesity and Metabolism described broad heterogeneity across trials, with lean mass accounting for about 15 percent of total weight lost in some studies and 40 to 60 percent in others.3
A quarter of total weight loss coming from lean tissue is not ideal. It is also not proof that a quarter of your weight loss came from functional skeletal muscle. Lean mass includes muscle, organs, body water, connective tissue, and glycogen-associated water. A drop in lean mass during rapid weight loss does not automatically mean an equal drop in contractile muscle or physical function.3
The 2026 SEMALEAN study adds important context. In 106 adults with obesity treated with semaglutide 2.4 mg for 12 months, mean weight loss reached 13 percent, lean mass dropped by about 3 kg at 7 months and then stabilized, handgrip strength improved by 4.5 kg, and the prevalence of sarcopenic obesity fell from 49 percent to 33 percent.4 That does not erase the risk. It does show why muscle function and body-composition context matter more than a single lean-mass number in isolation.
For lifters, the current evidence shows that GLP-1 therapy causes weight loss and that a meaningful fraction of that loss comes from lean tissue. The proportion varies widely with age, starting composition, rate of loss, protein intake, resistance training, and measurement method. The evidence so far does not point to a separate muscle-loss mechanism from the drug. It points to the usual muscle-retention challenge of a calorie deficit, with much less appetite, which can hide under-eating for weeks.
For the complete evidence review and the full data from every major trial, read how to preserve muscle on GLP-1 medications.
02Four factors to review
Four practical factors are worth reviewing on GLP-1 therapy. They can occur together, and fixing one while ignoring the others can leave gaps.
| Factor | What it does | Why it can get worse on GLP-1s |
|---|---|---|
| Protein intake falls | Fewer amino acids available for muscle repair and synthesis | Appetite suppression makes low protein easy to sustain for weeks without noticing |
| Training stimulus weakens | Muscle has less reason to be retained during a deficit | Low energy and nausea can make it harder to train hard or get to sessions |
| Rate of loss gets too fast | The body pulls more from lean compartments during aggressive deficits | The drug can make large deficits feel comfortable rather than alarming |
| Check-ins drop off | Early warning signs are missed | A moving scale can look like proof that the whole plan is working |
Protein intake on GLP-1 therapy often drops because appetite drops. Meals get smaller. Meals get skipped. The foods that feel tolerable on low-appetite days are often lower in protein. Over weeks, the daily protein average can slide well below the planned target without enough hunger to flag the shortfall.
When calories are low and energy is flat, it is common to train lighter, cut sessions short, or replace lifting with steps. Easing off to get through bad symptom days is reasonable. If the cutback lasts for weeks, it reduces the mechanical-tension signal that tells the body to hold onto muscle tissue, so the aim is to return to regular resistance training as symptoms allow. Protein without training is less effective. Training without protein is less effective. Neither alone does the full job.
The third and fourth factors can make the problem hard to see. The scale drops fast, which feels like success. Friends and family notice. The mirror is slow and unreliable at small magnitudes. Without regular checks of protein intake and lifts, a clear drop in training performance can be the first sign, after weeks of under-eating.
Why lifters are a different population than the trials studied
Most GLP-1 body-composition data comes from sedentary or lightly active adults with overweight or obesity. That population has different baseline muscle, different training history, different protein habits, and different responses to a calorie deficit than a man who has been lifting for years.
A man with a meaningful strength base who keeps resistance training during a deficit may be better placed to shift the weight-loss ratio toward fat than a sedentary trial participant who walks and eats a generic low-calorie diet. No trial has tested that directly in trained men on these drugs, so it remains a plausible expectation.
Protein intake, training, rate of loss and regular check-ins are the parts of the plan you can set up yourself, and they are easy to let slide when appetite is low. Your dose, age, health, sleep and genetics also shape how much of the weight loss is fat, and some of those are outside your control. When symptoms make eating or training hard, your clinician can help adjust the dose, the timeline or the plan.
Who is most at risk among men who train
Not every lifter on a GLP-1 faces the same level of lean-mass risk. Risk is likely higher with certain combinations of factors that compound each other.
| Higher-risk profile | Why the risk is elevated | What changes in the plan |
|---|---|---|
| Older lifter with a long training history | Some older adults show a smaller muscle response to the same protein dose. No single age cutoff applies to everyone | Discuss the higher end of the protein range with your clinician. Larger servings with about 3 to 4 g leucine are an option if appetite allows. Strength monitoring becomes the primary metric |
| Lifter with severe appetite suppression on any GLP-1, including tirzepatide or investigational retatrutide | Severe suppression makes a large deficit easy. More days per week below the protein floor | Pre-build liquid protein rescue meals. Consider a slower rate-of-loss target, such as 0.5 to 0.8% per week, with your clinician |
| Lifter who was already lean (below 18% body fat) before starting GLP-1 | Lower body-fat starting point means the body has less stored energy to draw from and pulls more from lean compartments | Smaller deficit. Slower rate of loss. More aggressive protein target. Consider whether the medication is the right tool |
| Lifter with a history of stop-start GLP-1 cycles | Weight regain after discontinuation may favor fat regain over muscle regain, creating a worse ratio each cycle | Build the off-ramp plan before starting. Plan protein and training for the months after the prescription ends |
| Endurance athlete using GLP-1 for weight loss during a training block | Appetite suppression collides with high fueling demands from endurance training. Recovery cost is already elevated | Protect carbohydrate around key sessions. Maintain at least 2 resistance sessions per week even during endurance phases. The full fueling, hydration, and load-management plan is in Endurance Training on a GLP-1 |
| Lifter whose training dropped well below his usual routine after starting the medication | Less training gives the body less reason to keep muscle during the deficit | One or two resistance sessions a week that include the main lifts can still be useful. Build back toward your usual frequency and intensity as symptoms allow, with your clinician's input. Protein alone does not replace the training signal |
Consider a man in his late 40s on a high dose of tirzepatide who has gone from four hard sessions a week to two light ones, whose protein has drifted from 170 grams to 90 grams, and whose scale is dropping 2 pounds per week. Several protections have slipped at the same time, and the medication can make it feel like a success because the weight is coming off and hunger is not a problem. Nothing in his log can tell him how much of the loss is muscle, and that is the reason to act on the inputs he can see. A check-in with his clinician about dose, rate of loss, protein and training makes sense now, before a clear drop in his lifts shows up in the log.
03Hit 1.6g/kg protein as the floor
Setting the floor that protects your lifts
The protein floor is an individualized daily planning target you set before a GLP-1-assisted cut starts. Research has not found a cliff below which lean-mass protection suddenly fails, and the right number differs from person to person. Calling it a floor is a planning choice. You decide the number in advance and defend it, even on the days when nothing sounds good and the thought of eating another chicken breast makes you want to skip the meal entirely.
The distinction between a floor and a range matters. A range says "aim for 1.2 to 2.2 g/kg and you will be somewhere useful." A floor says "do not go below this number, and here is the rescue plan for the days when you cannot eat." The floor gives you something to defend. The range gives you something to drift inside, and on a GLP-1 the drift usually heads toward the low end.
A 2025 joint advisory from four US obesity and nutrition societies notes that 1.2 to 1.6 g/kg per day has been proposed during active weight loss.5 The advisory does not set that range as a universal floor for GLP-1 users. It also says the right weight to base the math on is unclear in obesity. Actual weight, adjusted or ideal weight, and fat-free mass all give different numbers. Ask your clinician or a registered dietitian which weight to use, and whether kidney disease or another condition should limit your protein.
The trained-lifter targets in this article are practical guidance drawn from general sports-nutrition research. No GLP-1 trial has tested them. Meta-analysis and deficit-era trials support higher intakes for lean-mass retention in trained people, often around 1.6 to 2.2 g/kg and sometimes higher during aggressive cuts.67 Training status and your clinician's input decide where you land in that range.
04Where the floor sits by context
| Context | Daily protein guidance | Example per-meal amount | Why the target varies |
|---|---|---|---|
| General adult on GLP-1 | 1.2 to 1.6 g/kg/day | 25 to 35 g across 3 to 4 meals | Range the 2025 joint advisory says has been proposed during active weight loss. Weight basis set with your clinician |
| Trained lifter in a deficit | 1.6 to 2.2 g/kg/day | 30 to 45 g across 3 to 4 meals | Deficit upregulates protein oxidation. Training raises the payoff from adequate protein |
| Older lifter on GLP-1 | 1.6 to 2.0 g/kg/day | 35 to 45 g across 3 to 4 meals | Some older adults respond less to a given protein dose. Age alone does not set the target, so individualize it |
| Aggressive cut or strong suppression | Upper part of range, agreed with your clinician, + liquid protein backup | 30 to 50 g across 4 feedings | Margin for error disappears when meals shrink and appetite is unpredictable |
The three lifter rows are general training guidance to individualize with your clinician or dietitian. The joint advisory cautions against prolonged intake above 2 g/kg/day, which overlaps the upper end of these athlete ranges. Discuss the weight basis, duration and personal health context before choosing a target.5
For a 180-pound (82 kg) trained male lifter, the planning range lands at roughly 130 to 180 grams of protein per day, with 150 grams as a practical daily target to defend. For a 200-pound (91 kg) lifter, the range is roughly 145 to 200 grams, with 165 grams as the practical target. These numbers require planning. They do not happen by accident on days when appetite is suppressed.
05Meal distribution and leucine on GLP-1s
The daily total comes first. How you spread protein across meals is a practical second step, especially if a smaller appetite makes your daily target harder to reach.
When appetite is suppressed, meal size shrinks and per-meal protein drops with it. A plan that counts on one large dinner to make up the difference fails on the nights when that dinner never happens.
Leucine is the amino acid most closely tied to switching on muscle protein synthesis through mTORC1. The International Society of Sports Nutrition describes servings of about 20 to 40 grams of high-quality protein, carrying roughly 0.7 to 3 grams of leucine, as a useful dose, and notes that older adults may respond better toward the top of that range.8 An older lifter or a bigger man who can eat more might plan some meals around 30 to 45 grams of protein, which in whey, dairy, eggs or meat brings about 3 to 4 grams of leucine. That leucine amount sits above the ISSN range and comes from the larger serving, with no separate study behind it. Treat those as individual planning numbers. No study has set a leucine amount that every lifter, or every man past a certain age, has to reach at each meal.
Short-term lab studies of muscle protein synthesis support spreading protein across several meals as a useful option. Trials that measure body composition over weeks or months have not shown that spreading protein changes the result. In a 16-week trial that combined resistance training with a calorie deficit, 41 adults with overweight were assigned to eat 90 grams of protein a day, either as 30 grams at each of three meals or as 10, 20 and 60 grams. Body composition changes did not differ significantly between the groups.30 In an 8-week trial in young resistance-trained men, three and five high-protein meals a day at similar daily protein produced no statistically significant difference in lean mass, thigh muscle size or strength gains among the 18 men who finished.31 Both trials were small and tested one population and one protein dose each. They do not prove that every pattern works equally well. These trials did not test one meal per day or a 125-gram dinner.
So a man who eats 160 grams in a day as 20 grams at breakfast, 15 at lunch and 125 at dinner has still eaten 160 grams. On a GLP-1, a plan that depends on a large dinner can fall short if appetite makes that meal difficult to finish. Three or four meals of roughly 25 to 45 grams each make the total easier to reach, and getting there at breakfast and lunch is often the hardest part. The leucine threshold article covers the full science. Your total intake, overall diet and training decide the outcome far more than any single meal does.
| Body weight | Example per-meal protein | Number of daily feedings | Approximate leucine per meal |
|---|---|---|---|
| 70 kg (154 lb) | 25 to 35 g | 3 to 4 | 2 to 3 g |
| 82 kg (180 lb) | 30 to 40 g | 3 to 4 | 2.5 to 3.5 g |
| 91 kg (200 lb) | 35 to 45 g | 4 | 3 to 4 g |
| 105 kg (230 lb) | 40 to 50 g | 4 | 3 to 4 g |
These amounts are optional planning examples. If one meal comes in low, add the missing protein later in the day.
Liquid protein deserves more respect in this context than it gets in normal meal-planning advice. A shake is easier to finish than a chicken breast when appetite is low, and that makes it one of the most effective tools a lifter on GLP-1 has. Greek yogurt, whey isolate, casein, milk-based smoothies, and cottage cheese all solve the same problem. They raise protein distribution without forcing a large meal volume.
06Mapping protein pacing to the GLP-1 injection cycle
Weekly injectable GLP-1 medications like semaglutide and tirzepatide may not suppress appetite evenly across the week. The official Wegovy and Zepbound labels report when drug concentration peaks after each dose.2122 They do not describe a fixed appetite or symptom cycle that applies to everyone. If you notice a weekly rhythm in hunger and nausea, a log can help you plan around it.
One hypothetical pattern could look like this. Appetite suppression is strongest in the first one to three days after the dose. That is when food interest drops the furthest, meal size tolerance is lowest, and GI side effects like nausea are most likely to interfere with eating. By days 4 and 5, appetite comes back somewhat. By days 6 and 7, hunger is closest to normal before the next injection. Your timing may differ, and it can shift after each dose change. Log appetite, nausea, and protein grams by day after injection for two or three weeks to find your own pattern. The symptom-by-symptom playbook for nausea, constipation, reflux, and early satiety lives in Eating Through GLP-1 Side Effects.
If your log shows a pattern like this one, match the feeding strategy to the day. The table uses the example pattern above.
One possible pattern, drawn for illustration. It is not a pharmacological forecast. Your own log shows which days are hard for you.
| Days post-injection (example pattern) | Appetite level | Protein strategy | Meal architecture |
|---|---|---|---|
| Day 0 to 1 (injection day and next day) | Lowest | Pre-plan all meals. Default to liquid protein and small-volume, protein-dense foods | 2 small solid meals + 1 to 2 shakes. Do not wait for hunger to tell you to eat |
| Day 2 to 3 | Low | Continue planned meals. Eat the protein part first if that is easier to finish | 3 moderate meals with protein decided first, plus 1 shake if needed |
| Day 4 to 5 | Returning | Larger protein meals are easier to fit here if your log shows better appetite | 3 full meals with protein from food, plus pre/post-training nutrition if tolerated |
| Day 6 to 7 | Closest to normal | Aim for your usual target. Train as your plan and symptoms allow | 3 to 4 meals sized to appetite. No need to make up missed protein from earlier days |
A weekly rhythm also changes how you should think about training scheduling. If you have flexibility in when you train, put your hardest sessions on the days your log shows better appetite and energy, which are days 4 through 7 in the example pattern. That gives you a better fueling window around the training that matters most. Light or recovery sessions can go on the days when eating is hardest.
The practical move is to build two meal templates. One for your high-suppression days and one for moderate or normal days. Having both templates written down before you need them eliminates the decision fatigue that leads to missed meals on the worst appetite days.
The low-appetite meal toolkit
The meals that save your protein floor are the ones you can finish when nothing sounds good.
| Meal or snack | Protein | Calories | Why it works on GLP-1 |
|---|---|---|---|
| Whey isolate shake with milk | 35 to 40 g | 250 to 300 | Low volume, fast to consume, tolerable when appetite is gone |
| Greek yogurt (200 g) with protein granola | 30 to 35 g | 280 to 320 | Creamy texture is easier than solid food on nausea days |
| Cottage cheese (250 g) with fruit | 28 to 32 g | 250 to 300 | High protein density, no cooking required |
| Two eggs plus two egg whites scrambled | About 20 g | 200 to 240 | Small portion, fast to prepare, mild flavor |
| Deli turkey or chicken breast roll-ups (150 g) | 30 to 35 g | 180 to 220 | No cooking, portable, high protein per bite |
| Protein smoothie (whey, banana, milk, peanut butter) | 35 to 40 g | 350 to 400 | Drinkable, calorie-dense, works as a meal replacement |
| Canned tuna or salmon on toast | 28 to 32 g | 250 to 300 | Minimal prep, shelf-stable protein source |
| Casein shake before bed | 25 to 30 g | 150 to 180 | Slow-digesting, counts toward daily total, easy to finish |
| Edamame (200 g shelled) | 22 to 25 g | 240 to 260 | Snackable, high protein for a plant source, no cooking |
| Bone broth with added whey or collagen plus chicken | 25 to 30 g | 180 to 220 | Warm, sippable, gentle on GI side effects |
Protein in whey, casein, protein granola, and peanut butter varies by brand, so check your labels against these numbers.
Collagen peptides contribute dietary protein, but they are low in leucine and lack tryptophan. If you use collagen for connective-tissue support, count the labeled protein and include enough complementary sources such as whey, casein, eggs, meat, fish, dairy, soy, or legumes with grains.
If you need exact meals that solve this on bad appetite days, use Meal Templates for Low Appetite Days: High-Protein, Low-Volume Options. That page turns the protein floor into repeatable shake, bowl, roll, and soup structures you can actually clear.
What 150 grams of protein actually looks like on a GLP-1
For a 180-pound lifter targeting 150 grams as a daily floor, here is a realistic day built for moderate appetite suppression.
| Meal | Foods | Protein | Notes |
|---|---|---|---|
| Breakfast (8 AM) | Greek yogurt (200 g), protein granola (40 g), berries | 33 g | Small volume, protein-first, tolerable on low appetite |
| Lunch (12:30 PM) | Chicken or salmon bowl with rice, vegetables, light sauce | 40 g | Largest solid meal when appetite allows |
| Pre-training shake (3:30 PM) | Whey isolate (1 scoop) with banana and milk | 32 g | Drinkable, easy to finish, provides carbs for the session |
| Dinner (7 PM) | Lean protein (fish, chicken, lean beef) with roasted vegetables and small starch | 38 g | Protein source served first before sides |
| Pre-bed | Casein shake or cottage cheese | 20 to 25 g | Closes the gap from 143 g to the 150 g target |
| Daily total | 143 g before pre-bed, 163 to 168 g with it | The 150 g target needs the pre-bed feeding |
On high-suppression days, this architecture might need to shift. Replace the solid lunch with a shake. Replace the chicken bowl with a smaller protein-dense meal. The goal is the same. The food forms change to match what you can actually finish.
07Semaglutide vs. tirzepatide for recomposition
Choosing the right medication for a lifter's goals
Men who train often ask which GLP-1 medication is better for body recomposition. Neither drug was built for lifters. Both were designed and tested for weight management in populations that mostly do not resistance train. The question is which pharmacological profile creates conditions that a lifter can work with most effectively.
Semaglutide recomposition profile
Semaglutide is the most extensively studied GLP-1 receptor agonist for weight management. The STEP clinical trial program provides the primary evidence base.
For lifters, appetite and meal tolerance can change during semaglutide treatment, and the response varies by person and dose. In STEP 1, titration from 0.25 mg to the 2.4 mg maintenance dose took 16 weeks, and in practice it can take longer when a prescriber delays a step. Three meals and a planned protein snack or shake are one possible structure when tolerated. A rate-of-loss target is an individual planning choice to review with your clinician alongside training quality.
The STEP 1 DXA data showed that fat mass fell more than lean mass in both absolute and proportional terms, and lean mass as a percentage of total body weight actually increased because fat was lost faster.1 That matters for framing. The drug does not selectively target muscle. It creates weight loss, and the fraction that comes from lean tissue depends on the plan around it.
The SELECT trial added cardiovascular outcome data. Semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events by 20 percent in adults with overweight or obesity and established cardiovascular disease, without diabetes.9 That trial matters because it moves semaglutide beyond a weight-loss-only framing and into a cardiovascular risk reduction tool, which changes the clinical discussion for men who have both body-composition goals and cardiometabolic risk.
For lifters on semaglutide, meal planning, training and symptom monitoring are practical ways to support strength while losing weight. The trials do not establish how often trained lifters can maintain strength or tolerate a particular meal plan.
Tirzepatide recomposition profile
Tirzepatide is a dual GIP and GLP-1 receptor agonist. SURMOUNT-1 reported larger mean weight loss than STEP 1, but those were separate trials in different populations, so that comparison is not head-to-head. SURMOUNT-5 is the direct comparison, and it found greater mean weight loss with tirzepatide than with semaglutide 2.4 mg.11 The trial compared the two drugs and did not test which part of tirzepatide's action explains the difference.
SURMOUNT-1 showed mean weight reductions of 15.0 percent at 5 mg, 19.5 percent at 10 mg, and 20.9 percent at 15 mg, versus 3.1 percent with placebo at 72 weeks.10 SURMOUNT-5 compared tirzepatide head-to-head against semaglutide 2.4 mg and showed greater reductions in weight and waist circumference with tirzepatide, though the trial was not primarily designed to answer the body-composition question with the granularity that lifters want.11 It also did not compare how strongly each drug suppresses appetite.
For lifters, the planning questions are the same as on semaglutide. SURMOUNT-5 did not rank the two drugs by appetite suppression, and it did not show that one carries more muscle risk at the same rate of loss. Appetite, nausea and how much you can eat vary from person to person and from dose to dose on both drugs. So track what you actually eat and how you train after each dose step, and let that decide how much structure you need. If your weight is dropping faster than you planned, or GI symptoms are cutting into training during escalation, tighten the plan around protein and session timing. More total weight loss means more absolute lean mass at risk, even if the proportion of lean loss stays similar.
SURMOUNT-2 showed substantial weight loss even in adults with type 2 diabetes, with the 15 mg arm producing a mean reduction of 14.7 percent at 72 weeks.12 For a lifter with type 2 diabetes who has struggled to lose fat on previous approaches, tirzepatide is a strong option to discuss with a prescriber. Muscle is a major site of glucose disposal, so protecting it is a priority for men with type 2 diabetes on any weight-loss medication.
Tirzepatide now has cardiovascular outcome data in type 2 diabetes. SURPASS-CVOT randomized 13,299 adults with type 2 diabetes and established cardiovascular disease to tirzepatide up to 15 mg or dulaglutide 1.5 mg. Over a median of 210 weeks, tirzepatide was noninferior to dulaglutide for cardiovascular death, heart attack or stroke, with a hazard ratio of 0.92 (95.3% CI 0.83 to 1.01). Superiority was not established. In August 2026 the FDA added an indication to the Mounjaro label to reduce the risk of these events in adults with type 2 diabetes at high cardiovascular risk.32 The trial compared tirzepatide with another active GLP-1 drug, so it did not test tirzepatide against placebo, and it did not study people without diabetes.
08Planning framework for lifters on either drug
| Planning question | What the evidence shows | How to plan |
|---|---|---|
| Appetite and nausea | Both drugs reduce appetite and can cause nausea. SURMOUNT-5 did not compare how strongly each one suppresses appetite. Effects vary by person and dose | Note how much you eat in the days after each dose and adjust the plan to what you can tolerate |
| Reaching the protein floor | SURMOUNT-5 did not measure protein intake | A workable starting point is 3 meals plus 1 protein snack. Keep liquid protein on hand for days when solid food is hard to eat |
| Rate of weight loss | SURMOUNT-5 showed greater mean weight loss with tirzepatide than with semaglutide 2.4 mg. Individual rates vary widely on both | Many lifters aim for 0.5 to 1.0% of body weight per week. If you are losing faster and strength is dropping, a tighter range such as 0.5 to 0.8% is a reasonable adjustment to discuss with your clinician |
| GI side effects during titration | Both drugs commonly cause GI side effects, most often while the dose is being increased | Plan simpler meals and lighter sessions for the first 48 hours after each dose increase if that is when your symptoms occur |
| Titration schedule | Semaglutide steps up every 4 weeks toward a maintenance dose. Tirzepatide steps up by 2.5 mg after at least 4 weeks on the current dose. Zepbound's labeled maintenance doses for weight reduction are 5, 10 or 15 mg, chosen on response and tolerability | Review the meal plan before each step the prescriber makes and swap out the meal most likely to get skipped |
| Pre-workout nutrition | There is no drug-specific evidence for pre-workout timing | It matters on either drug, and most on days when you have eaten little |
| Meal structure | The structure you need depends on your appetite, nausea and schedule at your current dose | Add structure on low-appetite days and relax it when eating is easy |
| Cardiovascular outcome data | Semaglutide has SELECT, with a 20% MACE reduction versus placebo in adults without diabetes. Tirzepatide was noninferior to dulaglutide in SURPASS-CVOT in type 2 diabetes, and the Mounjaro label now carries a MACE risk-reduction indication for that group | Weigh this with your clinician as part of the treatment decision |
The protection protocol is the same for both medications. Lean-mass risk rises with low protein intake, fast weight loss, and missed or weakened training sessions during dose escalation, whichever drug you take. Larger total weight loss means more absolute lean mass at risk, so men who lose a lot of weight on either drug need to keep protein, training and monitoring consistent for the whole course.
If you want the medication-specific field manual for dose escalation, session placement, and maintenance-dose adjustments, read Tirzepatide and Zepbound: Training and Nutrition Plan for Lifters.
Neither drug is better for recomposition in every case. In SURMOUNT-5, tirzepatide produced more weight loss on average than semaglutide 2.4 mg. How much room for error you have depends on your own appetite, nausea and rate of loss at your dose, and the drug name does not predict those. The choice is a conversation between the lifter and their prescribing physician, factoring in starting weight, metabolic health, GI tolerance, insurance coverage, and how much structure the lifter is willing to build around the prescription.
Why dose increases are a risky window for lifters
Dose increases are a common point for protein intake and training quality to slip, because the meals that worked at the old dose may not fit the new one.
Both semaglutide and tirzepatide are titrated upward over weeks to months. In STEP 1, semaglutide started at 0.25 mg weekly and rose every 4 weeks through 0.5, 1.0 and 1.7 mg to 2.4 mg. Tirzepatide starts at 2.5 mg, and the prescriber can raise it in 2.5 mg steps after at least 4 weeks on the current dose. The Zepbound label lists 5, 10 or 15 mg as maintenance doses for weight reduction and tells prescribers to weigh response and tolerability, so the top dose is not the goal for everyone.22 A dose increase can change appetite or gastrointestinal symptoms, though the response varies by person and dose.
For lifters, each dose increase is a transition point where the meal architecture that worked at the previous dose may stop working. A man who was eating three solid meals at semaglutide 1.0 mg may find that at 1.7 mg, breakfast becomes impossible and lunch shrinks to half a plate. If he does not adjust the plan at each dose step, the protein floor breaks silently.
| Titration event | What typically changes | What to do before the increase |
|---|---|---|
| First dose increase | Appetite may drop further. GI symptoms may appear or worsen | Have liquid protein options ready. Identify the meal that is most likely to get cut and plan the replacement |
| Mid-titration (semaglutide 1.0 to 1.7 mg or tirzepatide 5.0 to 7.5 mg) | Appetite and tolerance may change during this step | Shift to the injection-day meal strategy for high-suppression days. Pre-plan all meals for the first 48 hours after each new dose |
| Reaching the maintenance dose your prescriber chooses | Appetite and meal tolerance vary. Some people may find their target harder to reach | Use the low-appetite rescue plan on high-suppression days. A shake-heavy day is a reasonable choice when solid food is hard |
The practical advice is simple. Before each dose increase, review your meal plan. Ask yourself whether each meal in the plan will still be tolerable at a higher level of appetite suppression. If the answer is no, swap the vulnerable meal for a smaller, denser, or liquid alternative before the increase arrives. Reactive adjustments cost protein days. Proactive adjustments protect them.
Where retatrutide fits in the comparison
Retatrutide is a triple agonist hitting GLP-1, GIP, and glucagon receptors. Company-reported topline results from the TRIUMPH-4 Phase 3 trial, announced in December 2025, showed 28.7 percent body weight loss at the 12 mg dose over 68 weeks in adults with obesity and knee osteoarthritis.13 That mean is larger than the ones reported in STEP 1 and SURMOUNT-1, but those were separate trials in different populations, so the comparison is not head-to-head. Lilly has since reported toplines from TRIUMPH-1 in May 2026 and from TRIUMPH-2 and TRIUMPH-3 in July 2026.2627 In October 2026, Lilly reported a head-to-head trial in adults with type 2 diabetes in which retatrutide produced greater A1C reduction and weight loss than semaglutide.25 That trial reported weight and A1C. It did not compare appetite suppression. TRIUMPH-5 compares retatrutide directly with tirzepatide. As of November 2026 it had finished enrollment and was still running, with trial dates through December 2026, and no results had been reported.36 Retatrutide is not FDA-approved, and the supply and safety questions for use outside a trial are covered below.
09Retatrutide interest among bodybuilders
Retatrutide produced 28.7 percent mean weight loss in the company-reported TRIUMPH-4 Phase 3 topline, a larger mean loss than the separate STEP 1 and SURMOUNT-1 trials reported. That number has drawn attention from people who want to cut fat outside a clinical trial. A March 2026 WBUR segment described how easy it was to buy vials sold as retatrutide from an overseas factory through a Discord server.18 No survey we found measures how many lifters use it, and there are no body-composition data from trained populations.
Why retatrutide draws lifters' attention
The appeal comes from the size of the weight loss and from what the glucagon component might add. Some of that story has human trial support, and some of it rests on mechanism and animal data.
The headline is the magnitude of the weight loss. The TRIUMPH-4 Phase 3 topline results, reported by Eli Lilly in a December 2025 press release, showed an average absolute weight loss of 28.7 percent (approximately 71 pounds) at the 12 mg dose over 68 weeks.13 That is placebo-adjusted weight loss of 26.6 percent. For comparison, semaglutide at its highest dose in STEP 1 produced 14.9 percent weight loss. Tirzepatide at its highest dose in SURMOUNT-1 produced 20.9 percent. Those numbers come from three separate trials with different populations and durations, so they show the size of each result rather than a head-to-head ranking.
TRIUMPH-4 enrolled adults with obesity and knee osteoarthritis, and its topline release did not report body composition. Nobody can predict from it how much fat or lean tissue a particular lifter would lose. The only published retatrutide DXA data come from a smaller Phase 2 substudy in type 2 diabetes, covered below.
Triple-agonist mechanism for body composition
Retatrutide is a single peptide that activates three receptor systems. In laboratory assays it was more active at GIP receptors, with roughly balanced activity at GLP-1 and glucagon receptors.38 The GLP-1 and GIP components work similarly to tirzepatide by suppressing appetite, slowing gastric emptying, and improving glycemic control. The glucagon receptor component is what makes retatrutide mechanistically distinct.
Glucagon receptor agonism has several proposed effects that could matter for body composition. The support comes from mechanism studies, animal work and one short human trial of a different drug.
| Proposed glucagon effect | Basis | What it might mean for lifters |
|---|---|---|
| More fat oxidation | In a 19-day randomized inpatient trial of 35 adults with overweight or obesity on a reduced-calorie diet, the GLP-1 and glucagon dual agonist SAR425899 raised fat oxidation and ketogenesis more than placebo39 | Might shift the energy source during a deficit toward stored fat. The trial used a different drug, and retatrutide trials have not tested this |
| Increased energy expenditure | In obese mice, the glucagon activity of retatrutide added to weight loss by raising energy expenditure38. In the SAR425899 human trial, 24-hour energy expenditure did not differ significantly from placebo39 | Might partly offset the slowdown in energy expenditure during a cut. Human evidence for this is not established |
| Reduced liver fat | In a placebo-controlled substudy of 98 adults with MASLD, a form of fatty liver disease, 12 mg retatrutide cut MRI-measured liver fat by 82.4% from baseline at 24 weeks. Placebo rose 0.3%37 | Relevant for metabolic health. The substudy had no tirzepatide arm. It measured blood biomarkers of fibrosis but had no biopsy-confirmed fibrosis endpoint, and it cannot show how much of the effect comes from glucagon |
| Glycemic counterbalance | Glucagon raises blood sugar on its own | The GLP-1 and GIP components raise insulin secretion, which is intended to offset this. Glucose effects in trials are a question for the prescriber |
The case for adding glucagon to GLP-1 and GIP is plausible, and mouse studies of retatrutide helped shape it.38 The SAR425899 trial is human evidence that dual GLP-1 and glucagon agonism can raise fat oxidation during a short diet.39 It tested a different drug for 19 days, so it does not isolate glucagon's contribution and does not show that retatrutide causes preferential body-fat loss.
Body composition data
The published body-composition data for retatrutide come from a Phase 2 DXA substudy in adults with type 2 diabetes, published in The Lancet Diabetes and Endocrinology in 2025. Of 189 people in the substudy, 155 had a baseline DXA scan and 103 completed treatment with scans at baseline and week 36.14
| Group | Total fat-mass change from baseline at week 36 |
|---|---|
| Retatrutide 0.5 mg | 4.9% reduction, not different from placebo |
| Retatrutide 4 mg (pooled) | 15.2% reduction |
| Retatrutide 8 mg (pooled) | 26.1% reduction |
| Retatrutide 12 mg | 23.2% reduction |
| Dulaglutide 1.5 mg | 2.6% reduction |
| Placebo | 4.5% reduction |
The abstract does not give a lean-mass percentage for any dose or report android or visceral fat. The authors judged that the proportion of lean mass loss to weight loss was similar to other obesity treatments, and wrote that a greater proportion of lean mass is not lost with retatrutide despite the larger weight loss.14 That judgment compares the substudy with separate published studies. The trial had no semaglutide or tirzepatide arm, so it cannot rank the three drugs. Lilly funded the trial, and all authors were Lilly employees and shareholders.
Those numbers need context for lifters. The study population was adults with type 2 diabetes, not resistance-trained men, and the trial did not test protein intake or a lifting program. DXA lean mass is also broader than skeletal muscle, since it counts water, glycogen-associated water, organs and connective tissue. No Phase 3 retatrutide body-composition results have been published yet.
For a lifter, the substudy gives no sign that retatrutide removes a larger share of lean mass than other obesity drugs, and it cannot show what protein and resistance training would add in trained men. Any benefit for a lifter's body composition is untested.
Safety and supply risks of using retatrutide outside a trial
Retatrutide is not approved by any regulator. It is an investigational drug in Eli Lilly's TRIUMPH Phase 3 program. Lilly reported company toplines from TRIUMPH-1 in May 2026 and from TRIUMPH-2 and TRIUMPH-3 in July 2026. It says it plans to submit an FDA application in the first quarter of 2027.252627 A planned filing does not guarantee approval or a date.
Outside a trial, there is no FDA-approved retatrutide product and no lawful compounded version for consumers. The FDA states that retatrutide cannot be used in compounding under federal law. In a September 2025 warning letter to an online seller, the agency explained why compounded retatrutide fails the conditions of sections 503A and 503B. Retatrutide has no USP or NF monograph, is not a component of an FDA-approved drug, and is not on the 503A or 503B bulks lists or tied to a drug on the shortage list. The FDA has also warned companies selling retatrutide and other GLP-1 drugs falsely labeled "for research purposes" or "not for human consumption." The Alliance for Pharmacy Compounding has told its members not to compound retatrutide.18 Vials sold outside regulated channels carry no regulatory check on identity, purity, potency or sterility.
In a March 2026 segment on WBUR's Here & Now, journalist Ezra Marcus described joining a Discord server he found through Reddit, where a sales representative for a Chinese factory sent him a menu of dozens of peptides. He paid $150 in Bitcoin and received a six-month supply sold as retatrutide in the mail two weeks later.18 The segment did not report any test of what those vials contained.
Several of these risks bear directly on training and eating.
| Risk | Why it matters for lifters | What the data shows |
|---|---|---|
| Dosing uncertainty | Training and nutrition plans depend on how much drug is actually in the vial. Without testing, nobody knows whether the real content matches the label, so the plan rests on a guess | No regulator checks gray-market vials, so the labeled dose cannot be trusted |
| GI side effects at clinical doses | Nausea, diarrhea, and vomiting directly impair protein intake and training quality | TRIUMPH-4 reported nausea in 43.2% of the 12 mg group versus 10.7% on placebo, with diarrhea in 33% and vomiting in 21% at 12 mg13 |
| Dysesthesia and skin sensitivity | Tingling, burning, or numbness in the skin, reported in 20.9% at 12 mg versus 0.7% on placebo in TRIUMPH-413. TRIUMPH-2 reported dysesthesia in 4%, 6% and 7% at 4, 9 and 12 mg versus 1% on placebo40. The Phase 2 obesity trial reported cutaneous hyperesthesia and skin sensitivity in 7% on retatrutide versus 1% on placebo41 | No data on how dysesthesia interacts with heavy training, grip-dependent lifts, or other drugs |
| Elevated heart rate | In the Phase 2 obesity trial, dose-dependent heart rate increases peaked at 24 weeks and declined after that41 | Adding stimulants, thyroid hormone or clenbuterol could raise cardiac load further, and no study has tested these combinations |
| Pancreatitis and gallbladder risk | The Wegovy and Zepbound labels list acute pancreatitis and acute gallbladder disease under warnings and precautions2122 | The WBUR segment described a bodybuilder who developed acute necrotizing pancreatitis after taking a large dose of retatrutide before a competition.18 One reported case cannot show how often this happens |
| No interaction data | Some users describe combining retatrutide with testosterone, growth hormone, and other peptides | We found no published interaction studies of retatrutide with anabolic steroids, growth hormone, or other peptides |
| Discontinuation rate | 18.2% stopped treatment because of adverse events at 12 mg in TRIUMPH-4, versus 4.0% on placebo, with some citing "perceived excessive weight loss" | Bodybuilders targeting specific weight classes or body-fat levels may need to stop or reduce dose at points not studied in trials |
Anti-doping status
Semaglutide and tirzepatide are not on the 2026 WADA Prohibited List. WADA lists markers of both drugs in its 2026 Monitoring Program, which tracks substances that are not prohibited so WADA can watch for patterns of use in sport.23 The 2026 list does not impose a blanket ban on approved GLP-1 receptor agonists.
Retatrutide is a different case. It is investigational, and Lilly said in October 2026 that no regulator anywhere has approved it.25 Section S0 covers pharmacological substances not addressed by subsequent sections of the List and not approved for human therapeutic use by any governmental regulatory health authority.24 Retatrutide appears to meet those criteria. That is our reading of S0, and WADA does not name retatrutide on the list. If you are a tested athlete, confirm its status with your national anti-doping organization before you use it, and ask them about Therapeutic Use Exemption options at the same time. TUE eligibility is assessed against WADA criteria and the individual circumstances.29
Competitors in untested organizations like the NPC or in non-tested powerlifting federations generally face no anti-doping consequence. Drug-tested federations such as USAPL, IPF, and CrossFit each publish their own rules and testing policies, and those rules are not identical. Check the current rules of the federation you compete in.
What users describe in forums
Forum and Discord posts describe self-directed dose schedules for retatrutide. This guide does not repeat them. Retatrutide has no approved dose for any use, the vials may not contain what the label says, and a schedule copied from a forum is not a protocol any regulator or trial has tested.
The examples below are individual self-reports on Reddit. Nobody in them can confirm what was in their vials, and a handful of posts cannot show how common any effect is or whether the drug caused it.
- One poster says they take testosterone and retatrutide and asks about adding tesamorelin. Replies in the same thread suggest growth hormone instead.43
- In a thread on what to combine with retatrutide, commenters suggest ipamorelin or tesamorelin, CJC-1295, and BPC-157 with TB-500. Some describe their own use and others are only making suggestions.44
- A runner says their heart rate on longer easy runs rose from about 160 to 165 bpm to 180 bpm, while they felt better and ran faster.45
- A user who had switched from tirzepatide describes a higher heart rate at work along with heavy sweating.46
- One commenter describes insomnia and running so hot at night that they woke up sweating.47
- A user about ten weeks in describes ongoing nausea, new reflux and stomach pain, and difficulty eating.48
No study has tested retatrutide combined with any of those other compounds. Adding retatrutide to semaglutide or tirzepatide would stack drugs acting on the same GLP-1 receptor, and no data support doing that.
The absence of medical oversight in this kind of use is the central problem. A clinical trial has a monitoring infrastructure that catches adverse events early. A man injecting grey-market retatrutide purchased through a Discord channel with cryptocurrency has no monitoring infrastructure beyond his own subjective experience and whatever blood work he orders independently. The safety signals that emerged in TRIUMPH-4, particularly dysesthesia at a 20.9 percent incidence, were detected because the trial was designed to look for them. A bodybuilder experiencing tingling or burning sensations might attribute them to training, a pinched nerve, or another compound in the stack rather than recognizing a drug-specific adverse effect.
10Protein floor on retatrutide
The protein floor applies on retatrutide just as it does on semaglutide and tirzepatide. No trial has shown that retatrutide suppresses appetite more than either drug, and the TRIUMPH-4 weight-loss result does not by itself show greater lean-tissue risk. Appetite effects vary from person to person and from dose to dose. If you lose a lot of total weight, though, even a typical lean-to-fat ratio adds up to more pounds of lean tissue. Use your own appetite log to decide how much to rely on the protection systems in this article.
A hypothetical arithmetic example, not a result or prediction for any drug or person. The 25% lean share is assumed. Actual body-composition changes vary, and DXA lean mass includes more than muscle.
| Variable | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Mean weight loss in the cited arm | 14.9% at 2.4 mg (STEP 1) | 20.9% at 15 mg (SURMOUNT-1) | 28.7% at 12 mg (TRIUMPH-4, company-reported) |
| Appetite suppression | Varies by person and dose | Varies by person and dose | Varies by person and dose |
| Protein target for trained lifters | Same individualized target, often 1.6 to 2.2 g/kg/day | Same individualized target | Same individualized target |
| Liquid protein backup frequency | As needed | As needed | As needed |
| Rate-of-loss planning | Individualized | Individualized | Individualized |
| Meal structure | Adjust to appetite and routine | Adjust to appetite and routine | Adjust to appetite and routine |
| Regulatory status | FDA-approved for obesity | FDA-approved for obesity | Investigational. Not approved. FDA says it cannot be compounded |
The weight-loss row compares separate trials, which is not a head-to-head result. No trial has compared protein prescriptions across these three drugs, so the protein target stays the same in every column. The appetite row does not rank the drugs because responses vary and the cited head-to-head outcomes did not compare appetite suppression. The liquid-protein, rate-of-loss and meal-structure rows are planning options to match to your own appetite log. None of them is a threshold tested in a GLP-1 trial.
The rate-of-loss guardrail deserves emphasis on any drug that makes eating very little feel easy, retatrutide included. Without an agreed intake plan and a rate-of-loss target, a very large deficit can degrade training quality and may shift the weight-loss ratio toward more lean tissue. How tight to set that target is an individual decision with your clinician. No trial has set a dose-specific threshold. In one Reddit thread about strength on retatrutide, some users report losing strength and others report holding or gaining it. One who reports gaining strength adds that they are on testosterone replacement.49 Reports like that cannot show the drug's effect on lean mass by itself.
What the retatrutide evidence does and does not show
Retatrutide produced a 28.7 percent mean weight loss in TRIUMPH-4, larger than the means reported in the separate STEP 1 and SURMOUNT-1 trials. In a head-to-head trial in type 2 diabetes, Lilly reported greater weight loss and A1C reduction than semaglutide, and the direct comparison with tirzepatide, TRIUMPH-5, had no reported results as of November 2026.36 The Phase 2 DXA substudy authors judged that the lean share of weight loss was similar to other obesity treatments. The glucagon receptor component offers a plausible route to more fat oxidation, with mouse data on retatrutide and one short human trial of a different dual agonist behind it.3839 For a bodybuilder whose main goal is fat loss during a cut, the appeal is easy to see.
The limits are just as concrete. Retatrutide is not approved. There is no legal compounded supply, and the FDA has warned sellers marketing it as a research chemical. Skin sensitivity was reported in Phase 2, and the Phase 3 trials reported dysesthesia at higher rates in some arms, so the safety picture is still developing. We found no trials of retatrutide in resistance-trained people or in combination with the other drugs some bodybuilders describe using with it. Lilly also reported a 104-week TRIUMPH-1 extension, but it enrolled a selected group. Participants had a baseline BMI of at least 35 and had completed 80 weeks and tolerated treatment. In that group, people on 12 mg or their maximum tolerated dose averaged 30.3 percent weight loss at 104 weeks.26 That result applies to people who stayed on the drug, not to everyone who starts it. Longer-term safety is still under study.
Semaglutide and tirzepatide already provide strong, evidence-backed, legally prescribed options for the same recomposition goal with established safety profiles and real manufacturing oversight. The large weight loss in retatrutide trials is real. Outside a clinical trial, though, there is no approved prescription route in the US. A man interested in retatrutide can ask his clinician about enrolling in a trial, and in the meantime discuss the approved options.
For the full evidence-tier framework that places retatrutide alongside approved drugs, growth hormone secretagogues, research peptides, and collagen, read Peptides for Body Recomposition.
11Training programming for a GLP-1 cut
The training strategy that gives muscle a reason to stay
Protein supplies the building materials. Resistance training gives the body a reason to use them for muscle. Protein without resistance training leaves the body with less reason to keep muscle during a calorie deficit. On GLP-1 therapy this matters more, because low appetite makes it easy to drift into a low-calorie, low-activity pattern that looks like progress on the scale.
Walking is good for metabolic health, energy expenditure, and adherence. It is not the main muscle-retention tool on these medications. A man who swaps all his lifting for 10,000 steps a day because the drug makes him tired loses the stimulus most tied to keeping muscle. When fatigue builds, the first options are usually trimming volume, eating something before training, and looking at sleep. Lighter loads, shorter sessions or a rest day are also reasonable on bad symptom days, an injury or poor recovery. The aim is to return to regular resistance training as you are able.
The 2026 review in Current Obesity Reports argued that structured progressive resistance training should be built into obesity-pharmacotherapy care when lean-mass preservation matters.19 Treat it as part of the plan from the start.
Keep intensity and trim volume first
Training load and effort are the main signals to keep muscle. Volume carries much of the recovery cost. During a medication-assisted deficit, recovery can suffer because calories are lower and GI symptoms may disturb sleep. When something has to give on an ordinary tired day, trimming volume first usually costs less than dropping the load.
In practice, that means keeping the loads on your main lifts close to your pre-cut levels when you feel well enough. Reduce sets before reducing weight, and cut accessory work before compound movements. When symptoms, pain or an injury make heavy work a bad idea, lighter loads, a different exercise or a rest day is the right call, and you can build back as you recover.
| What to keep when you can | What to reduce first | What to protect over the weeks |
|---|---|---|
| Loads on anchor lifts (squat, bench, deadlift, press) | Accessory volume (isolation work, arms, abs) | Some compound lifting with meaningful loads |
| Effort on working sets (RPE 7 to 9) | Junk volume (sets you add out of habit, not stimulus) | Regular resistance training as symptoms allow |
| 3 to 4 weekly sessions | Extra conditioning that competes with recovery | Lower-body loading most weeks, adjusted for joints |
| Progressive overload tracking | Failure training and very high-fatigue techniques | Sleep and recovery support |
A 12-week GLP-1 cut training block
A 12-week block is a convenient length for a first cut phase before reassessing whether to continue, move to maintenance, or discuss the medication plan with your prescriber. This block is designed for a lifter with at least one year of consistent resistance-training experience who is titrating onto or already at a stable dose. Every number in it is a starting point to adjust for symptoms, injuries and recovery.
Phase 1 ramp in weeks 1 through 4
The goal is to establish baseline performance, learn how the medication affects appetite and energy, and build the feeding rhythm.
| Variable | Target |
|---|---|
| Weekly sessions | 3 full-body or upper/lower sessions |
| Volume | Usual pre-cut volume if recovery allows. Trim it if symptoms or recovery require |
| Intensity | Moderate to hard. Establish baseline numbers on 2 to 4 anchor lifts |
| Monitoring focus | Daily weight, daily protein grams, training-log entries |
During the ramp phase, you are calibrating. You are learning which days post-injection are hardest for eating, how your energy changes across the week, and what your baseline strength numbers are before the deficit deepens. There is no need to cut volume in advance, and no need to hold it if recovery is clearly struggling.
Phase 2 main cut in weeks 5 through 10
The goal is to keep anchor-lift performance steady or improving while the deficit continues, and to manage fatigue mostly through volume.
| Variable | Target |
|---|---|
| Weekly sessions | 3 to 4 sessions. Upper/lower or push/pull/legs depending on schedule |
| Volume | Reduce accessories by 20 to 30 percent from Phase 1 if recovery demands it. Keep compound volume where recovery allows |
| Intensity | RPE 7 to 9 on working sets on good days. Lighter work on symptom days is fine |
| Key metric | Anchor-lift performance. If load or reps decline for 2 consecutive weeks, review food, sleep and symptoms before changing the program |
Appetite can be at its lowest during dose increases in this phase. Pre-workout food helps protect training quality. A slow decline in strength can come from under-eating, poor sleep, symptoms, accumulated fatigue or an injury, so check all of them. More food around training is often part of the fix, and so is a lighter week when recovery needs it.
Phase 3 consolidation in weeks 11 through 12
The goal is to test strength, deload if accumulated fatigue is high, and reassess targets for the next phase (continued cut, maintenance, or a medication discussion with your prescriber).
| Variable | Target |
|---|---|
| Weekly sessions | 3 sessions |
| Volume | Reduce total volume by 30 to 40 percent. Keep intensity on 2 to 3 key lifts if you feel well |
| Intensity | Test anchor lifts at or near pre-cut levels if joints and symptoms allow. Use the results to inform next steps |
| Decision point | Stable or improved strength is a good sign that training and food are supporting you, though it cannot measure lean mass. If strength dropped substantially, consider a maintenance-calorie period before continuing the deficit |
12Anchor lifts and how to use them as guardrails
An anchor lift is a compound movement that you track consistently across the entire cut. It serves two purposes. First, it provides the mechanical-tension signal that tells your body to retain muscle. Second, it acts as an early-warning system for under-fueling and recovery problems.
Pick 2 to 4 compound lifts. Good options for most lifters include a squat variation, a press (bench, dumbbell or overhead press), a hip hinge (deadlift or Romanian deadlift), and a pull (barbell row, lat pulldown, or weighted pull-up). Track load and reps on these lifts every session.
| Anchor-lift pattern | What it can mean | What to do |
|---|---|---|
| Load and reps stable or improving | Training and food are supporting performance. It does not measure lean mass | Keep going |
| Small decline on one lift for one week | Normal noise. Fatigue, sleep, or a bad day | Do nothing different. Reassess next session |
| Decline on 2 or more lifts for 2 consecutive weeks | Under-eating, poor sleep, symptoms, fatigue, or a minor injury | Review protein and food intake over the last 7 days. Check sleep, symptoms and rate of loss. Eat more if intake was low |
| Significant decline across all lifts for 3 or more weeks | The deficit may be too large, or something else needs attention | Discuss with your clinician. Raising intake, adding pre-workout food and reducing volume are options to try |
Anchor lifts give faster feedback than the mirror or the scale. Strength can change within weeks, while visible body-composition change is slow and hard to judge. Strength and lean mass do not always change together, and a lift can drop for reasons unrelated to muscle, so a falling squat is a reason to review food, sleep and symptoms. It cannot tell you what a DXA scan would show, or when.
Session-level nutrition for lifters on GLP-1s
Skipping food before training is easy on a GLP-1 medication. Appetite is low, so the pre-workout meal gets dropped, and the session can feel flat. Whether that matters depends on what you ate in the previous day and how hard the session is. A morning session after a normal dinner is different from a session after two days of very low intake.
Planned food before and after training helps most on low-intake days. Adjust the amounts to what your stomach tolerates.
| Session type | Pre-workout (60 to 90 min before) | Post-workout (within 2 hours) | Low-appetite fallback |
|---|---|---|---|
| Standard lifting day | 20 to 30 g carbs + 15 to 25 g protein | 30 to 40 g protein | Banana + small protein shake before. Full shake after |
| Hard lower-body or high-volume day | 30 to 50 g carbs + 20 to 30 g protein | 35 to 45 g protein + 30 to 50 g carbs | Rice cake with honey + protein shake before. Full meal after if tolerable |
| Low-appetite training day | 15 to 20 g fast carbs + any tolerable protein | 25 to 35 g protein even if appetite is poor | Sports drink + handful of deli turkey before. Whey shake after |
Carbohydrate around training deserves emphasis. Protein preserves tissue. Carbohydrate protects session quality. After several days of very low carbohydrate intake, bar speed and rep quality can drop, and the training that protein is meant to support gets weaker. People on GLP-1 medications often under-eat both protein and carbohydrate, then try to solve the whole problem with more protein powder. That misses the mechanism. Muscle is preserved best when protein intake is adequate and training quality stays high enough to create repeated anabolic demand.
For the drug-specific training and protein execution layer, read protein targets and training strategy on semaglutide or retatrutide.
Sample exercise selection by training level
The anchor lifts and exercise selection should match the lifter's experience level. More advanced lifters can tolerate more exercise variety. Less experienced lifters benefit from simplicity during a pharmacologically assisted cut because cognitive bandwidth and motivation are already taxed.
Beginner to early intermediate (1 to 3 years of consistent lifting)
3 sessions per week, full-body.
| Session | Exercise 1 | Exercise 2 | Exercise 3 | Exercise 4 | Exercise 5 |
|---|---|---|---|---|---|
| A | Squat 3x6 to 8 | Bench press 3x6 to 8 | Barbell row 3x8 to 10 | Dumbbell overhead press 2x10 to 12 | Face pulls 2x15 |
| B | Romanian deadlift 3x8 to 10 | Incline dumbbell press 3x8 to 10 | Lat pulldown 3x8 to 10 | Leg press 2x10 to 12 | Bicep curls 2x12 to 15 |
| C | Deadlift 3x5 to 6 | Overhead press 3x6 to 8 | Chin-ups 3x6 to 10 | Leg curl 2x10 to 12 | Lateral raises 2x12 to 15 |
Anchor lifts to track: squat (Session A), bench press (Session A), deadlift (Session C). These three movements give you a simple weekly read on whether your strength is holding.
Intermediate to advanced (3 or more years of consistent lifting)
4 sessions per week, upper/lower split.
| Session | Focus | Key exercises | Working sets |
|---|---|---|---|
| Lower A | Squat emphasis | Back squat 4x4 to 6, Romanian deadlift 3x8 to 10, leg press 3x10 to 12, leg curl 2x10 to 12 | 12 total |
| Upper A | Press emphasis | Bench press 4x4 to 6, dumbbell row 3x8 to 10, overhead press 3x8 to 10, face pulls 2x15 | 12 total |
| Lower B | Hinge emphasis | Deadlift 3x3 to 5, front squat or goblet squat 3x8 to 10, walking lunge 2x10 to 12 each leg, calf raise 3x12 to 15 | 11 total |
| Upper B | Pull emphasis | Weighted chin-up 4x4 to 6, incline dumbbell press 3x8 to 10, cable row 3x10 to 12, lateral raise 2x12 to 15 | 12 total |
Anchor lifts to track: back squat (Lower A), bench press (Upper A), deadlift (Lower B), weighted chin-up (Upper B).
During Phase 2 of the cut (weeks 5 through 10), one option when ordinary fatigue rises is to drop the last 1 to 2 accessory exercises from each session and keep the first 3 to 4 exercises and their loads. If fatigue is still high after that, you could remove one working set from the secondary compound. When symptoms, pain, an injury or poor recovery are the problem, lighter loads on any lift, including the anchor lifts, or a rest day are reasonable choices.
Men over 40
The same principles apply with two common modifications. First, many lifters find that one or two extra warm-up sets help their joints feel ready during a deficit. That is a comfort and readiness choice, and no trial has shown that extra warm-up sets prevent injury. Second, exercise selection may shift toward movements that load the target muscle while managing joint stress. A leg press may replace a barbell squat if the knee or lower back cannot tolerate heavy squatting in a deficit. A trap-bar deadlift may replace a conventional deadlift. The principle remains the same. Load the muscles. Create mechanical tension. Track the performance.
What to do when training feels flat
Training fatigue on a GLP-1 cut is common. It can be a normal cost of dieting, or a sign that something needs attention. Work through these checks in order, knowing that more than one can apply at once.
- Check food and protein intake over the last 3 to 5 days. If the average is below your target, low intake may be part of the cause. Raise it where you can.
- Check sleep. Disrupted sleep from GI side effects or general life stress can slow recovery. If sleep has been poor, address it before changing training.
- Check pre-workout nutrition. If you have been training on very little food because appetite was low, try a small pre-workout snack you can tolerate.
- Check your rate of loss over the last 14 days. If you are losing more than about 1 percent of body weight per week, the deficit may be larger than your training can support. Talk with your clinician about raising intake. As an illustration, some plans add 100 to 250 kcal per day around training, but the right amount depends on your intake, symptoms and medical picture.
- Check symptoms and joints. Nausea, dizziness, pain or a nagging injury are reasons to train lighter or rest, and persistent symptoms belong with your prescriber.
- If those checks look fine, reduce training volume by 15 to 20 percent and keep intensity on anchor lifts if you feel well. Reassess in one week. If you need the order for what to trim, read Strength Training Minimum Effective Dose During a Cut.
A lighter week, a deload or a few days off are legitimate options. The pattern to avoid is a permanent swap of lifting for steps or cardio, because that removes the resistance-training stimulus for weeks while the deficit continues.
13Rate-of-loss guardrails
When fast becomes a problem
The scale is the most rewarding number to watch and says little about what kind of tissue is being lost. Fast weight loss feels like success. It gets compliments. It validates the decision to start the medication. Sports nutrition guidance for lean athletes often favors slower loss to help keep lean mass, and how far that applies on GLP-1 therapy has not been tested.
The general framework from fat loss and muscle preservation applies here with a GLP-1-specific adjustment. The medication can make large deficits feel comfortable. Without a planned pace, a lifter can drift into a rate of loss that would feel miserable in a non-medicated cut and feels fine when appetite is low.
14The guardrail framework
| Rate of loss (14-day average) | Interpretation for a lifter | Action |
|---|---|---|
| 0.5 to 0.8% body weight per week | Practical example zone for many lifters. Sports nutrition uses paces like this to give fat loss room to outpace lean-mass loss | Keep going. Continue monitoring anchor lifts and symptoms |
| 0.8 to 1.0% body weight per week | Can be fine if strength is steady and protein intake is near target | Monitor closely. Slow down if strength starts to slip |
| Above 1.0% body weight per week for 2 or more weeks | The deficit may be larger than training and recovery can support, even if it feels manageable | Discuss with your clinician. A modest increase around training, sized to you, is one option |
| Weight dropping fast and meals are being skipped regularly | Weight loss is coming from not eating rather than from a plan | Rebuild meal structure and agree an intake plan with your clinician or dietitian |
For a 200-pound man, 0.5 to 0.8 percent per week is 1.0 to 1.6 pounds. That feels slow compared to what the medication can produce. Sports nutrition uses paces like this to give a lifter a better chance of losing fat while keeping strength. GLP-1 trials have not tested it as a body-composition target, so treat it as a starting example and review it with your clinician alongside your lifts, symptoms and health goals.
Consider two hypothetical men over 12 weeks. One loses 30 pounds, of which a DXA scan estimates 8 pounds as lean mass. The other loses 20 pounds, with 3 pounds estimated as lean mass. Lean mass made up about 26.7 percent of the first man's weight loss and 15 percent of the second man's. That ratio describes the weight lost, and it says nothing about how much of either man's starting lean mass remains. The example cannot tell you who is stronger, healthier or better placed for maintenance, and the first man also lost more fat. It shows why total weight lost is an incomplete scoreboard.
Why the drug makes fast loss feel fine
This is the same under-eating pattern described above, applied to the rate of loss. The drug quiets the signals (hunger, food noise, meal-seeking behavior) that would normally tell you the deficit has gone too far. A 200-pound man can eat 1,400 calories and feel satisfied. The scale rewards the behavior. Your food log and training log are two of the earliest places to spot the problem, though neither one measures body composition.
Setting an intake plan
Beyond a protein target, it helps to have an agreed daily intake range for the cut. There is no validated formula for that range on GLP-1 therapy. Simple multipliers such as body weight in pounds times 10 to 12 are rules of thumb that have not been tested in people on these drugs. A better approach is to set an individual plan with your clinician or a registered dietitian, based on your goals, training load, rate of loss, health conditions and what you can tolerate, and then adjust it from your trend.
On low-appetite days, liquid calories and protein can help you get closer to that plan. A shake, a glass of milk or a protein smoothie are often easier than a plate of food. If you cannot eat enough day after day, or cannot keep fluids down, contact your prescriber. Persistent inability to eat or drink is a medical issue to raise with them, and more shakes are not the fix.
Setting your deficit by body-fat starting point
The rate-of-loss guardrail interacts with your starting body composition. Men with higher body fat may tolerate larger deficits with less lean-mass cost because they have larger fat stores to draw from. As body fat decreases during the cut, a smaller deficit usually makes sense.
| Starting body-fat estimate | Example deficit on GLP-1 | Example rate of loss | Lean-mass risk level |
|---|---|---|---|
| Above 25% | 500 to 750 cal/day | 0.7 to 1.0% body weight per week | Lower. The body has substantial fat reserves to draw from |
| 18 to 25% | 350 to 500 cal/day | 0.5 to 0.8% body weight per week | Moderate. Protein intake and training become more important |
| Below 18% | 200 to 400 cal/day | 0.3 to 0.5% body weight per week | Higher. Protein, training and pace all need attention. Discuss whether the medication fits your goals at this body-fat level |
These rows are planning examples drawn from sports nutrition, and no GLP-1 trial has tested them. Body-fat estimates from scales and calipers can be off by several percentage points, so treat the bands as rough. A man who starts at 28 percent body fat on semaglutide may have more room to lose quickly in the early weeks. A man who started at 22 percent, or who has already lost 20 pounds and is nearing 18 percent, may need a smaller deficit and closer monitoring. The medication does not adjust the deficit to match your changing composition, so review the rate-of-loss trend and your intake plan with your clinician as you get leaner.
This is also where the distinction between body recomposition and weight loss becomes practical. Body recomposition, losing fat while preserving or gaining muscle, requires a narrower deficit and more precise nutrition than simple weight loss. The deeper into a cut you go and the leaner you get, the more the plan must shift from "lose weight" to "change composition." The medication helps with the appetite side. It does not make the precision side easier. If anything, it makes it harder because the appetite suppression can mask the signals that would normally tell you to eat more.
15Track weight lifts protein and waist weekly
The monitoring system that catches problems early
If you only watch the scale, you cannot tell what kind of tissue you are losing. Four simple measures give you more to go on. Each is an imperfect proxy, and none measures muscle directly. Read together, and reviewed with your clinician, they show when the plan needs adjusting.
Metric 1 is the 14-day weight trend
Weigh yourself daily, at the same time, under the same conditions. Pay less attention to the daily number and more to the 14-day average.
Daily numbers swing with water, sodium, bowel timing and the slower stomach emptying these drugs cause. A 14-day average smooths much of that out. A trend of 0.5 to 0.8 percent body weight loss per week fits the example pace in this guide. A trend above 1.0 percent per week for more than two weeks is worth discussing with your clinician. A flat or rising trend can mean intake has crept up, water has shifted, or you have reached maintenance.
Metric 2 is anchor-lift performance
Anchor lifts are one of the earliest signals you can track yourself. A decline can show up long before the mirror changes. It can come from under-eating, poor sleep, symptoms, fatigue or a minor injury, and it does not measure lean mass.
Track load and reps on 2 to 4 compound lifts every session in a training log or notebook. Use a simple format: exercise, weight, sets, reps. Compare week over week.
| Pattern | Interpretation | Response |
|---|---|---|
| Stable or improving over 4 or more weeks | Training and food are supporting performance. It does not prove lean mass is preserved | Continue |
| One bad session | Normal variation. Sleep, stress, hydration | No change needed |
| Two consecutive weeks of decline on 2 or more lifts | Under-eating, poor recovery, symptoms or another cause | Review protein, pre-workout food, sleep, symptoms and rate of loss |
| Three or more weeks of decline across all lifts | The deficit may be too large for your current routine, or something else needs attention | Discuss with your clinician. Raising intake, possibly toward maintenance, is one option |
Metric 3 is daily protein grams
Log food in Fuel or another tracker to estimate your protein intake. Food logs are estimates, because portions, labels and database entries all carry error, so look at the weekly pattern more than any single day.
Flag days well below your target. A single low day happens. A week where the average sits below your target usually points to a meal that keeps coming up short. Logged intake below target for a couple of weeks is a reason to adjust the plan. It cannot tell you whether you are losing muscle.
When the weekly protein average drops below your target, look at the meals before looking at motivation. Add a default protein source to a meal that is consistently weak. Add a shake. Prepare protein-dense foods that need no decisions.
Metric 4 is waist measurement
Measure your waist every two weeks under the same conditions. Same time of day, same location (at the navel, relaxed), same state (fasted or consistent timing relative to meals). Record it with a tape measure in a notebook or wherever you keep your training log.
Waist size tracks fat loss around the middle better than the scale alone, though bloating and constipation can shift it. If your waist is shrinking while weight drops and strength holds, that is an encouraging pattern. If weight drops but waist is stable and strength is declining, review food, training and recovery. If waist and weight both rise, the deficit has likely stalled.
| 14-day weight trend | Waist trend | Strength trend | Interpretation |
|---|---|---|---|
| Down 0.5 to 0.8%/wk | Shrinking | Stable or up | Encouraging pattern. Keep going |
| Down more than 1.0%/wk | Shrinking | Declining | Possibly too fast. Review the pace and intake with your clinician |
| Down 0.5 to 0.8%/wk | Stable | Declining | Review protein, training, sleep and symptoms |
| Flat or up | Stable or up | Declining | Several things may need attention. Do a full review |
Optional metrics for deeper tracking
These are useful but not required for most lifters.
A DXA scan every 8 to 12 weeks gives an estimate of fat, lean soft tissue and bone, but it is expensive and infrequent. Hydration, recent meals and glycogen shifts affect the lean estimate, so scan under similar conditions each time. It helps confirm a trend and is too slow for catching early problems. Progress photos taken monthly with standardized lighting and positioning show whether the visual result matches the data. Step count and general activity deserve attention because a lifter whose step count drops by 3,000 per day over three weeks is burning less energy each day. Handgrip strength is a simple, cheap functional test some men over 40 like to track.
Use Fuel's Timeline to see food, workouts and weigh-ins day by day, and the weekly review to check your protein and weight trend each week. Keep anchor-lift loads and waist measurements in your training log, and look at them alongside the review. A weekly check makes problems easier to spot, though no routine catches everything.
If you want the shorter execution page built specifically around keeping muscle while the scale is moving, read GLP-1 Muscle Retention Guide for Men. It covers the week-to-week operating decisions, age-band adjustments, and the dose-level meal planning that turn the system into a running plan.
16Testosterone and GLP-1 therapy
GLP-1 therapy, testosterone, and lean-mass preservation in men
A March 2026 narrative review in Cureus examined testosterone replacement therapy as a possible way to preserve lean mass in men with persistently low serum testosterone who are taking GLP-1 receptor agonists.15 The authors found no randomized trials that tested the two treatments together. They described the idea as biologically plausible, since testosterone therapy raises lean mass in men with low testosterone and GLP-1 weight loss includes some lean mass, and they did not support routine combined use.
That leaves a hypothesis worth discussing with a clinician for men who meet the diagnostic criteria for hypogonadism. It is not a recommendation for men on GLP-1 therapy to add testosterone.
When this conversation matters
This is a conversation for your clinician, and testosterone is not something to self-prescribe. The relevant question is whether you have clinical hypogonadism, which is different from a disappointing week in the gym.
The Endocrine Society guideline recommends diagnosing hypogonadism only in men who have symptoms and signs of testosterone deficiency together with consistently low testosterone. It recommends a fasting morning total testosterone measurement with an accurate assay as the first test, and confirming a low result with a repeat morning measurement.33 A single blood draw during a hard cut cannot sort out whether the cause is low testosterone, under-eating, poor sleep or something else. Your clinician weighs symptoms, other possible causes and repeat tests together.
| Situation | Why it matters | What to do |
|---|---|---|
| Strength regression that persists after improving protein, sleep, and rate of loss | Many causes are possible, low testosterone among them | Raise it with your clinician, who can decide whether testing is appropriate |
| Fatigue and low libido beyond what the deficit explains | Low testosterone symptoms overlap with under-eating, poor sleep and other conditions | Ask your clinician to assess the symptoms and other causes. Testing, if needed, uses repeated morning samples |
| Older men on aggressive GLP-1 cuts | Testosterone tends to fall with age, and a large deficit can add strain. Age alone is not a reason to test | Discuss symptoms with your clinician. Testing is guided by symptoms and signs, not by age |
| Men with pre-existing low testosterone starting GLP-1 therapy | The medication does not treat low testosterone. Weight loss may improve it or may not | Discuss testosterone management as part of the treatment plan from the start |
What this does not mean
Testosterone replacement therapy is not a general recommendation for GLP-1 users. Supraphysiologic testosterone use is a different conversation with different risks, different legal rules, and different evidence. If a man on GLP-1 therapy keeps losing strength after improving food, sleep and pace, low testosterone is one clinical question among several, and a clinician should assess it.
Weight loss and testosterone
Obesity itself is linked with lower testosterone. Many men with obesity have lower testosterone than they would at a lower body weight, and losing weight can raise it. A 2013 meta-analysis of 24 studies found that both low-calorie diets and bariatric surgery raised total testosterone in men with obesity, with larger rises after surgery, and that the amount of weight lost best predicted the rise.34 No study in that analysis used GLP-1 drugs, so the size of any rise on these medications is not known.
That means GLP-1 therapy might raise testosterone through weight loss, while a very large energy deficit could push in the other direction. The net effect depends on the individual, the rate of loss and the starting hormone level. A man whose testosterone was low before starting GLP-1 therapy is in a different situation from a man whose low reading reflected excess body fat.
Timing changes what a result means. A testosterone level measured at week 8 of an aggressive GLP-1 cut can differ from one taken after weight has stabilized. If you have symptoms that worry you, raise them with your clinician, who can decide whether and when repeated morning testing makes sense.
17Meal architecture for GLP-1 lifters
Building meals that survive appetite suppression
The meal architecture for a lifter on GLP-1 therapy serves a different purpose than a normal meal plan. In a normal cutting diet, the challenge is managing hunger. On a GLP-1, the challenge is eating enough of the right things when you are not hungry. The plan needs to work on days with low motivation.
Eating protein first when appetite is limited
Deciding the protein source for each meal before anything else is a simple planning habit. Eating that part of the plate first is an option on low-appetite days, when you can tolerate it.
On a GLP-1 medication, fullness can arrive well before the plate is empty, and the point varies from person to person and meal to meal. If you start with vegetables and starches on a low-appetite day, you may feel full before reaching the protein. Starting with the protein makes it more likely you finish that part.
Carbohydrate, fat, fruit and vegetables still matter for training fuel, fiber and overall nutrition, so they belong in the plan in their own right. On days when appetite is strong enough for a full meal, the order barely matters. Some people find a few bites of something else first settles their stomach, and that is fine too.
Three-meal plus one-shake default day
This is one meal template for trained men on GLP-1 therapy. It covers much of the protein target before any pre-bed feeding, includes carbohydrate around training, and keeps portions moderate.
The following day is built for a 180-pound (82 kg) trained male lifter targeting 150 to 165 grams of protein daily.
| Meal | Foods | Protein | Calories |
|---|---|---|---|
| Breakfast (8:00 AM) | Greek yogurt (200 g) with mixed berries (100 g) and protein granola (40 g). Or two eggs plus four egg whites scrambled with one slice of whole-grain toast | 30 to 35 g | 300 to 350 |
| Lunch (12:30 PM) | Grilled chicken breast (150 g cooked) or salmon (150 g cooked) over rice (100 g cooked) with roasted vegetables and a light dressing. Or a turkey and avocado wrap with edamame, checked against labels | About 51 g with chicken. About 38 to 43 g with salmon | 450 to 550 |
| Training shake (3:30 PM) | Whey isolate (1 scoop) mixed with a banana, 200 ml milk, and optional tablespoon of peanut butter | 30 to 35 g | 280 to 380 |
| Dinner (7:00 PM) | Protein source (fish, chicken thigh, lean beef, or firm tofu, 150 to 180 g cooked or as sold) with roasted or steamed vegetables and a small starch | About 37 to 52 g with fish, chicken thigh or lean beef. About 29 to 36 g with firm tofu | 400 to 550 |
| Daily total | About 127 to 173 g, depending on protein choices | 1,430 to 1,830 |
Protein per 100 g differs a lot between these foods. USDA values are about 31 g for roasted chicken breast, 25 g for chicken thigh, 22 g for farmed and 25 g for wild cooked Atlantic salmon, 23 g for cooked cod, 26 g for broiled 93% lean ground beef, and 17 g for raw firm tofu, with about 3 g in 100 g of cooked white rice.35 The meal figures in these tables include about 3 to 5 g from the rice, vegetables and starch served with the protein. Tofu firmness and brands vary, so check the label. Protein in yogurt, granola, whey, casein, and peanut butter also varies by brand. Adjust portions to match your own target.
Three meals and the shake land at about 127 to 173 g. If your logged total falls short of your chosen target, a pre-bed feeding or another protein-rich food can help close the gap. A casein shake adds 25 to 30 g depending on the label, and 200 g of 1% cottage cheese adds about 25 g.
These meals add up to 1,430 to 1,830 kcal. They are the protein-containing core of a day, and they are not a complete daily intake for most men who train. Build the rest of the day with carbohydrate, fat, fruit, vegetables and snacks to match the intake plan you set with your clinician or dietitian, your training and what you can tolerate.
How the template scales by body weight
The 180-pound template above is the middle of the range. A 160-pound man needs less total protein but the same meal structure. A 230-pound man needs substantially more protein and may need an extra feeding, depending on the target he picks and how much he actually eats. Here is how the architecture changes.
| 160 lb (73 kg) | 180 lb (82 kg) | 230 lb (104 kg) | |
|---|---|---|---|
| Example daily target | 117 to 130 g | 150 to 165 g | 166 to 195 g |
| Breakfast protein | 25 to 30 g (Greek yogurt + granola, or 2 large eggs + 3 large egg whites + 1 slice whole-grain toast) | 30 to 35 g (200 g Greek yogurt + 40 g protein granola + berries) | 40 to 45 g (3 large eggs + 2 large egg whites + 100 g cottage cheese + 1 slice whole-grain toast, or large yogurt bowl with double protein granola) |
| Lunch protein | About 31 to 35 g with 120 g cooked salmon or cod over rice, or about 42 g with 120 g cooked chicken breast | About 38 to 43 g with 150 g cooked salmon, or about 51 g with 150 g cooked chicken breast | About 49 to 56 g with 200 g cooked salmon, or about 67 g with 200 g cooked chicken breast. A double-protein burrito bowl varies, so check the restaurant's nutrition information |
| Training shake | 25 to 30 g (1 scoop whey + banana) | 30 to 35 g (1 scoop whey + banana + milk) | 40 to 45 g (1.5 scoops whey + banana + milk + PB) |
| Dinner protein | About 33 to 39 g with 130 g cooked fish, chicken thigh or lean beef plus sides. About 26 to 28 g with 130 g firm tofu | About 37 to 52 g with 150 to 180 g cooked fish, chicken thigh or lean beef plus sides. About 29 to 36 g with firm tofu | About 49 to 63 g with 200 to 220 g cooked fish, chicken thigh or lean beef plus sides. Firm tofu gives less, about 38 to 43 g |
| Pre-bed (if needed) | Usually not needed if other meals hit targets. Add a casein shake or cottage cheese if the day lands below 117 g | Casein shake or cottage cheese, 25 to 30 g | Depends on your chosen target and actual intake. Casein shake or cottage cheese, 25 to 35 g, if the day lands below target |
| Daily total | About 107 to 141 g from 3 meals + shake, depending on protein choices | About 127 to 173 g from 3 meals + shake, depending on protein choices | About 167 to 220 g from 3 meals + shake, depending on protein choices |
| Energy intake | Set individually with your clinician or dietitian. These meals are the protein-containing core of the day | Set individually. These meals supply about 1,430 to 1,830 kcal before other foods | Set individually with your clinician or dietitian. These meals are the protein-containing core of the day |
| Key difference | Meals are smaller, so protein-dense choices leave room for the target. Less room for low-protein sides | The baseline template | Meal volume is the challenge. With chicken breast at lunch and meat at dinner the day can pass 200 g, more than many targets need, so smaller portions are fine. A second shake or a pre-bed feeding helps when meals come in under plan |
A larger lifter may have a higher protein target while also finding meals difficult during low-appetite periods. Appetite suppression varies by person, medication and dose. Protein-rich meals, a pre-bed snack or a shake can help reach an agreed target when they fit the person’s appetite and routine.
Low-appetite day rescue plan
On the high-suppression days your log flags, the solid-food plan may not be realistic. The rescue plan replaces one or two solid meals with liquid protein so you still get close to your target.
Rescue template A with three shakes plus one meal
| Feeding | What | Protein |
|---|---|---|
| Morning shake | Whey + milk + banana | 33 g |
| Midday shake | Casein + Greek yogurt, mixed | 30 g |
| Small solid meal (whenever appetite allows) | Chicken breast, rice, vegetables (or equivalent) | 35 g |
| Evening shake | Whey + milk + peanut butter | 33 g |
| Daily total | 131 g |
Rescue template B with two meals plus two shakes
| Feeding | What | Protein |
|---|---|---|
| Breakfast | Greek yogurt + berries + protein granola | 32 g |
| Midday shake | Whey isolate + milk | 30 g |
| Solid meal (afternoon or evening) | Lean protein + starch + vegetables | 38 g |
| Pre-bed shake | Casein + milk | 28 g |
| Daily total | 128 g |
These totals sit about 20 grams below the example target for a 180-pound lifter. No research has set a protein minimum for a bad day, so treat them as a practical fallback. On a hard appetite day, about 130 grams is a lot closer to most targets than the 60 grams you might eat without a plan. Shake-based days also tend to be low in energy, fiber and some micronutrients, so add milk, fruit, oats or other foods you can tolerate.
When low-appetite days become the norm
If your log shows severe appetite suppression on most days of the week, on any GLP-1 medication, tell your prescriber. Eating very little for weeks is a reason for clinical review of the dose, the pace and your nutrition, and planning more shakes is not enough on its own. In the meantime, use whichever rescue template you tolerate and add solid food when you can.
Injection-day meal strategy
If your log shows lower appetite on injection day or the day after, plan those days before they arrive.
Before injection day, have the following ready.
Two pre-made protein shakes in the refrigerator. One for morning, one for whenever appetite allows. A batch of pre-cooked protein (chicken, ground turkey, hard-boiled eggs) that requires no cooking or decision-making. A simple written plan for what you will eat and when, regardless of appetite.
On injection day itself, eat on a schedule rather than waiting for hunger signals. Set reminders if needed. If your log shows that hunger fades after the dose, waiting for it may mean eating very little that day.
Meal prep for the week
Decision fatigue compounds appetite suppression. When everything sounds unappealing and you also have to decide what to cook, the default outcome is skipping the meal.
The fix is a two-day prep approach that takes 90 minutes and covers most of the week.
On prep day 1 (Sunday or Monday), cook 1.5 to 2 kg of protein in bulk. Chicken breast, ground turkey, salmon, or a combination. Portion into containers with a scale. Each container should hold one meal's worth of protein (150 to 180 g cooked). Cook a batch of rice or potatoes. Wash and prep vegetables.
On prep day 2 (Wednesday or Thursday), refresh the protein supply if running low. Prep a second round of vegetables. Restock Greek yogurt, cottage cheese, and protein powder.
The goal is to make the protein-floor-hitting version of every meal the easiest option in your kitchen. If the prepped chicken container is faster than ordering delivery, you will eat the chicken. If it is not, you will not.
Hydration and fiber on GLP-1 therapy
Constipation is one of the common side effects of GLP-1 medications. It affects training indirectly by causing bloating, discomfort, and reduced appetite for solid food, which further depresses protein intake. It also affects quality of life in ways that erode adherence over weeks.
The mechanism is straightforward. GLP-1 drugs slow gastric emptying. Reduced food intake means reduced fiber. Reduced fluid intake, which often accompanies reduced appetite, compounds the problem. The combination of slower gut motility, less fiber, and less water makes constipation more likely.
A few habits from the first week can help prevent it.
| Habit | Example target | Why it matters on GLP-1 |
|---|---|---|
| Water intake | Around 2.5 to 3.5 liters per day is a common example for an active man, more in heat or after heavy sweating. Adjust to your losses, and follow your clinician's advice if you have kidney, heart or other conditions that affect fluids | Dehydration worsens constipation and can impair training performance. Eating less also means less water from food |
| Fiber from food | 25 to 35 grams per day from vegetables, fruit, legumes, and whole grains | Fiber feeds gut motility. When total food volume drops, fiber drops with it unless you target it specifically |
| Fiber timing | Spread across meals rather than in one large dose | A sudden large fiber load on a GLP-1-slowed gut can cause bloating and gas. Gradual, consistent intake is better tolerated |
| Electrolytes | Adequate sodium, potassium, and magnesium through food or supplementation | Reduced food intake can lower electrolyte intake. Food sources are a good first step |
Drink water across the day, not just at meals. Set a reminder if needed. When meals shrink or get skipped, the drinks that came with them often get skipped too. Dehydration during a training program can reduce performance, worsen GI side effects, and make scale readings swing more.
If constipation persists despite adequate fiber and hydration, discuss it with your clinician. There are medical interventions beyond dietary changes that can help, and chronic untreated constipation can limit how effectively you can eat and train during the cut.
Eating out on GLP-1 therapy
Restaurant meals bring their own planning questions. Portions are large, protein content is often unlisted, and when appetite is low the dishes that appeal may not be the most protein-dense ones.
Restaurant meals can be enjoyable and still fit the plan. Choosing a dish with a clear protein source makes your target easier to reach.
Look at the protein options first and build the meal around one you like. You do not have to finish anything. On a GLP-1, leaving half a plate is common. Take the rest home for later when appetite may be better.
Easy restaurant choices on a GLP-1 include grilled fish or chicken with a side vegetable, sushi with extra fish, poke bowls with extra protein, Greek restaurants (grilled meats, yogurt-based sides), and any place where you can order a plain protein source with a simple side. Pasta and other favorite dishes fit too. A pasta with chicken, seafood or a meat sauce, or a side of grilled protein, keeps the meal protein-rich. Buffets and rich sauces make portions harder to judge, so log your best estimate.
If the restaurant meal looks light on protein, a planned protein snack before or after can close the gap.
18Supplements worth considering on a GLP-1 cut
What is worth taking and what is noise
Few supplements marketed for recomposition, fat loss, or muscle preservation have been tested in people taking GLP-1 drugs. A few have good general evidence in people who train, and whether that carries over to GLP-1 therapy is mostly untested. None of them is required, and food, protein and training come first.
Creatine monohydrate
Creatine is one of the best-studied sports supplements for strength and lean mass in people doing resistance training. It raises phosphocreatine stores in muscle, which improves performance in short, high-intensity efforts. Better training quality is the most likely route to any lean-mass benefit.
For a man on a GLP-1 medication, the case rests mainly on training. If creatine helps you get one more rep on a squat set during a low-energy session, that rep adds to the training stimulus. The evidence for creatine comes mostly from resistance-training studies in people not taking these drugs. Evidence that it preserves lean mass specifically during a calorie deficit is thinner, and no trial has tested it in people on GLP-1 therapy.
A common dose is 3 to 5 grams per day. Loading phases are optional. Take it at any time of day, with or without food. Creatine can cause some water retention, often noticeable in the first weeks and more likely after a loading phase, so the scale may tick up. The amount varies from person to person, and some people see little change. That water is not fat gain and is not a reason to stop. Judge your 14-day weight trend once your weight settles after starting.
One common concern on GLP-1 therapy is whether creatine worsens GI side effects. There is no strong evidence that 3 to 5 grams of creatine monohydrate daily causes meaningful GI distress in most people. If you notice stomach discomfort, take it with a meal rather than on an empty stomach.
If you want the full decision guide on when creatine is worth it, how to handle the water-weight issue, and how to test it inside Fuel without misreading your cut, read Creatine While on GLP-1: Worth It for Fat Loss and Strength?.
Vitamin D
Vitamin D levels tend to be lower in adults with obesity, and little sun exposure or a small diet can lower intake further. Vitamin D matters for bone and muscle function. When total food intake is low, diet alone may supply less than usual.
Whether to test vitamin D, and how much to take, depends on your risk factors, such as little sun exposure, darker skin, bone-health concerns, a very restricted diet or conditions that affect absorption. Your clinician can decide whether a 25-hydroxyvitamin D test makes sense and, if you need a supplement, what dose fits. Correcting a deficiency supports bone and general health. Taking more once your level is adequate has not been shown to help keep muscle during weight loss.
Omega-3 fatty acids
Omega-3 supplements (EPA and DHA from fish oil or algae) have shown positive results in older adults. In a randomized trial of 60 healthy adults aged 60 to 85, six months of fish oil increased thigh muscle volume, handgrip strength and one-repetition maximum strength compared with corn oil.42 Those participants were not dieting or taking GLP-1 drugs. Whether they help keep lean mass in people on GLP-1 drugs is unknown, because no trial has tested it. They can be a reasonable choice for general health if you eat little fish.
Lower-priority supplements
Fat burners, thermogenics and CLA have little evidence for preserving muscle and can carry their own side effects. BCAAs add little if you already reach your protein target from complete protein sources. Testosterone boosters sold as supplements are not a substitute for a clinical assessment of low testosterone. Protein, training, pace and monitoring do far more than any of these, so set those up first.
HMB has some evidence for preserving muscle in older adults and during bed rest, often in multi-nutrient formulas. No GLP-1-specific outcome trial has tested it for lean-mass preservation.20 That missing trial means the effect in GLP-1 users is unknown, which is different from showing it does not work. The HMB evidence review explains why findings from bed rest and multi-nutrient clinical formulas do not transfer directly to medication-assisted weight loss.
The micronutrient side of the plan deserves its own treatment, because the protein floor is necessary and not sufficient. Calcium, vitamin D, iron, magnesium, potassium, and B12 are the gap profile to watch when total intake sits near 1,200 to 1,500 kcal per day, especially for older adults and higher-risk patients who also need separate bone-health screening. The density math, the food anchors, the supplement stack, and the lab audit are in The GLP-1 Micronutrient Floor. For men over 50 with any fracture risk factor, a prior fragility fracture, chronic glucocorticoid use, or a low-BMI trajectory, the baseline-DXA decision, the least significant change ceiling on follow-up scans, and the structured response when BMD declines on therapy is the parallel skeletal playbook in GLP-1 Medications and Bone Density: The DXA Monitoring Playbook.
19Plan the exit before you stop the drug
Planning the exit before you need it
The strongest GLP-1 withdrawal studies show a consistent pattern. Continued treatment maintains weight loss. Discontinuation leads to regain. In the STEP 4 trial, 902 people took semaglutide during a 20-week run-in. The 803 who reached and tolerated the 2.4 mg dose by week 20 had lost a mean 10.6 percent of body weight, and they were then randomized to continue the drug or switch to placebo. From week 20 to week 68, weight rose 6.9 percent on placebo and fell a further 7.9 percent with continued treatment.16 The separate STEP 1 extension was an exploratory follow-up of a subset of trial participants. In that subset, people who stopped semaglutide after 68 weeks regained about two-thirds of their prior weight loss within a year.28 SURMOUNT-4 showed the same pattern with tirzepatide, with placebo participants regaining 14.0 percent from randomization.17
That regain happens because the drug was doing a substantial portion of the appetite-control work. When treatment stops, hunger returns, meal size drifts up, food reward signals strengthen, and the old intake pattern starts rebuilding. Long-term treatment is a legitimate choice. The Zepbound label covers weight reduction and long-term maintenance, and STEP 4 and SURMOUNT-4 show that continuing treatment maintained the loss better than stopping.221617 Whether you stay on or plan to stop, habits built during treatment help. A lifter who built protein habits, training consistency and a monitoring routine has more to work with if the dose changes or the medication stops. Those habits support the outcome, and they cannot guarantee that weight stays off after stopping.
The pre-stop checklist for lifters
If you and your clinician decide to stop or reduce the medication, build the plan during the last month on treatment, when appetite is still manageable and new routines are easier to set up.
| Pre-stop task | Target | Why it matters |
|---|---|---|
| Set the protein target | Keep the target you used during the cut, set with your clinician. This guide starts lifters at 1.6 g/kg/day | Protein supports satiety and training as appetite returns |
| Confirm resistance training is stable | 3 to 4 weekly sessions with hard sets, as your health allows | Training supports muscle and strength as intake rises |
| Estimate maintenance intake | Track intake and weight for 2 to 3 stable weeks | Maintenance needs often change after a large loss |
| Establish 3 to 5 default meals | Breakfast, lunch, dinner, and 2 fallback meals | When hunger rises, you need decisions already made |
| Set an action threshold | Example: intervene if 14-day average weight rises more than 2% from stop weight | Small regain is easier to stop than late regain |
| Discuss the plan with your clinician | Taper, direct stop, dose reduction, restart option, or alternative medication | A vague medication plan creates panic decisions later |
The full off-ramp protocol, including what to do in the first eight weeks off, how to manage the appetite rebound, and when to restart or change treatment, is covered in how to stop GLP-1s without rapid fat regain.
20When to involve your clinician
The signals that mean this is not a nutrition problem
Some patterns during GLP-1 therapy point to medical risk rather than a nutrition or training problem you can solve by adjusting meals or programming. Treat these as reasons to contact your clinician instead of adjusting the plan on your own.
| Signal | What it can indicate | Next step |
|---|---|---|
| Severe, persistent abdominal pain with vomiting | Pancreatitis or gallbladder complication risk | Stop self-adjustments. Seek urgent clinical evaluation |
| Inability to keep fluids down, or repeated dehydration | Electrolyte and kidney stress | Seek urgent medical care. Do not train until fluids are back to normal |
| Fainting, confusion, or severe weakness | Hypoglycemia or systemic stress, especially if using diabetes medications concurrently | Urgent evaluation |
| Strength regression that persists for 3 or more weeks after improving food, sleep, pre-workout nutrition and rate of loss | Possible hormonal, metabolic, or medical issue beyond diet | Ask your clinician to assess it. Any tests, such as thyroid, metabolic or repeated morning testosterone, follow from symptoms and examination |
| Persistent significant nausea, vomiting or poor intake that keeps you well below your food or protein plan | The dose or pace of escalation may not suit your current tolerance | Contact your prescriber promptly. You do not need to wait two weeks |
The role of your physician in GLP-1 therapy extends beyond writing the prescription. Dose titration, side-effect management, metabolic monitoring, and discontinuation planning are all clinical decisions. A qualified provider should be able to explain their monitoring protocol, their approach to dose adjustment, and their strategy for what happens after treatment. If they cannot, that tells you something about the quality of care you are receiving. The best peptide advice from Huberman, Attia, Patrick, and Ferriss podcast roundup covers provider selection criteria in more detail.
21An example 12-week cut
A progression with nutrition and training adjustments
A falling weight trend still needs checks on food intake and training. This hypothetical example shows how those checks could guide adjustments during a cutting phase. All values and outcomes are invented for illustration, not measured results or expected individual outcomes.
The hypothetical lifter is 34 years old, 205 pounds, approximately 24 percent body fat, with 3 years of consistent lifting, starting prescribed semaglutide injections for the first time. Protein floor set at 160 grams. Anchor lifts at baseline: squat 275x5, bench 205x5, deadlift 335x5.
Medication dose and titration belong to the prescribing clinician, guided by the official Wegovy prescribing information. This nutrition and training example provides no dosing schedule.
| Week | Weight (14-day avg) | Rate of loss | Protein avg | Squat | Bench | Deadlift | Key event or adjustment |
|---|---|---|---|---|---|---|---|
| 1 | 205.0 | Baseline | 148 g | 275x5 | 205x5 | 335x5 | Begins prescribed treatment. Appetite barely changes. Sets baseline numbers |
| 2 | 204.2 | 0.4%/wk | 152 g | 275x5 | 205x5 | 335x5 | Protein below floor 3 days. Adds a morning shake on injection days |
| 3 | 203.1 | 0.5%/wk | 158 g | 275x5 | 205x6 | 340x5 | Slight nausea on injection day |
| 4 | 201.8 | 0.6%/wk | 161 g | 280x5 | 205x5 | 340x5 | Phase 1 complete. Weekly protein average above floor. Strength stable or up |
| 5 | 200.4 | 0.7%/wk | 155 g | 275x5 | 205x5 | 335x5 | Appetite drops noticeably. Lunch shrinks |
| 6 | 198.6 | 0.9%/wk | 143 g | 275x5 | 200x5 | 335x5 | Protein below floor. Bench dips. Adds pre-bed casein shake |
| 7 | 197.2 | 0.7%/wk | 162 g | 275x5 | 205x5 | 335x5 | Protein average back above floor. Bench returns to baseline |
| 8 | 195.5 | 0.9%/wk | 158 g | 275x5 | 200x5 | 330x5 | Hardest week. GI side effects days 1 to 2. Switches to rescue template on injection days |
| 9 | 193.8 | 0.9%/wk | 163 g | 275x5 | 205x5 | 335x5 | Protein average above floor. Drops 2 accessory exercises per session |
| 10 | 192.3 | 0.8%/wk | 160 g | 270x5 | 200x5 | 335x5 | Squat dips 5 lbs. Adds 30 g carbs pre-workout. Waist down 2.5 inches total |
| 11 | 191.0 | 0.7%/wk | 164 g | 275x5 | 205x5 | 335x5 | Consolidation phase. Reduces volume 35%. Squat returns to baseline |
| 12 | 189.8 | 0.6%/wk | 162 g | 275x5 | 205x5 | 340x5 | Final test. All anchor lifts at or above baseline |
The hypothetical figures end 15.2 pounds below the starting weight, with a 2.5-inch reduction in waist measurement. At week 12, all three anchor lifts are at or above baseline. The weekly protein intakes average about 157 grams per day, below the example's 160-gram floor.
The protein average is below 160 grams in weeks 1 to 3, 5 to 6, and 8. At least one anchor lift is below baseline in weeks 6, 8, and 10. Food adjustments appear alongside recovery in the example, but these invented values cannot establish what caused it. Training volume also changes. Two accessory exercises are removed per session in week 9, and volume drops 35 percent in week 11.
Stable or recovering strength is useful to monitor. It does not prove muscle retention or establish how much of the weight change is fat, muscle, or water. Use food and training trends to identify what needs review, and bring medication tolerance or dosing questions to the prescriber.
22Run the Sunday audit inside Fuel
The Sunday night audit that keeps the cut on track
The system here has four metrics, two meal templates, and a set of decision rules. Fuel holds your food, workouts and weigh-ins. Your training log and tape measure hold the rest. Together they make a short weekly routine.
- Check the weight trend. Open Trends in Fuel, choose the 14-day view, and look at the direction of your weigh-ins rather than any single day. A loss of 0.5 to 0.8 percent per week fits the example pace. A loss above 1.0 percent for two or more weeks is worth raising with your clinician, along with your intake plan. Connect Fuel to Apple Health so weight entries from your scale sync automatically.
- Check protein. Look at your logged daily protein totals for the past seven days. They are estimates, so look for patterns. If one or two days came in low, that is ordinary. If most days were well below your target, look at macros by meal to see whether the gap is a specific meal, such as breakfast or lunch on injection days, or a general drift. That tells you whether you need a rescue template for specific days or a broader change.
- Check the training log. Look at your anchor lifts over the last two weeks in your own training log. Fuel's Timeline shows workouts alongside food and weigh-ins, which helps you line up hard sessions with what you ate. Stable or rising lifts are a good sign, though they do not prove lean mass is preserved. If two or more lifts are down for two consecutive weeks, look at food, sleep, symptoms and recovery. Several causes are possible, and more than one can apply.
- Record the waist measurement. Every two weeks, measure your waist at the navel and note it in your log. Compare it to the weight trend and the strength trend using the interpretation table in the scoreboard section above. A shrinking waist while weight drops and lifts hold is an encouraging pattern.
Most weeks the audit takes a few minutes. Run it every Sunday or Monday alongside the weekly review. Catching a slide at week 6 gives you more room to adjust than finding it at week 10.
Open Fuel today, set a protein target with the get leaner and stronger goal, using 1.6 g/kg as a starting point to adjust with your clinician, and log your next three days of food.
23Common GLP-1 cut mistakes that cost muscle
Each of these patterns is easy to fall into when appetite is low.
Treating the scale as the scoreboard
A weight trend sustained over a couple of weeks helps you judge whether the plan is working, while a single day's reading cannot tell you whether you are in a deficit. Neither can show whether the loss is fat or muscle. Use the four-metric scoreboard (weight trend, anchor lifts, protein grams, waist), knowing that each is a proxy. Trials report lean mass making up anywhere from about 15 percent to 40 to 60 percent of the weight lost, so a man who watches only the scale has no way to tell where he falls.3
Replacing lifting with walking
Walking is excellent for metabolic health, mood, energy expenditure, and adherence. It does little to keep muscle on its own. The man who drops from four lifting sessions to one and replaces the other three with long walks loses most of his resistance-training stimulus. A better approach is to keep lifting as regularly as your health allows and add walking alongside it.
Eating one meal per day because the drug makes it easy
Intermittent fasting works for some people. On a GLP-1 medication, appetite suppression can make one meal a day feel comfortable even when it leaves someone short on energy or protein. Check whether the food you actually eat meets your daily target and supports your training. Three to four feedings with planned protein are one practical way to spread the intake across a day. No study has shown that a specific meal pattern is required to keep muscle, and small trials that held daily protein steady found no significant difference between even and skewed meals30 or between three and five meals a day.31 The practical concern is whether a single meal provides enough total food for your needs.
Ignoring pre-workout nutrition because you are not hungry
"I train fasted because I am not hungry in the morning" is easy to say on GLP-1 therapy. Training before breakfast is not automatically a problem. A morning session after a normal dinner the night before can go fine. It becomes a problem when it follows a day or two of very little food, when glycogen and recent protein intake may both be low. On those days, a small snack or shake 60 to 90 minutes before training can help if you tolerate it. A banana and a half-scoop of whey is a small option many people can manage. Low hunger does not tell you how much food your training needs.
Relying on collagen alone
Collagen peptides can contribute protein, but they are low in leucine and lack tryptophan, so they should not be the sole protein source. Count their labeled protein and include enough complementary sources such as whey, casein, eggs, meat, fish, dairy, soy, or legumes with grains.
Not adjusting the plan at each dose increase
A titration step can change appetite or gastrointestinal symptoms, although responses differ by person and dose. The meal plan that worked at semaglutide 0.5 mg may not work at 1.7 mg. Lifters who keep the same plan through each dose step can run short on protein for weeks without realizing why. Treat each dose increase as a checkpoint to review and update your meals.
Building no habits that outlast a dose change
Whether you stay on the medication long-term with your clinician or stop after reaching a goal, the habits you build during treatment help with what comes next. A man who reaches his target on a GLP-1 with no protein habits, no default meals and no monitoring routine has less to fall back on if the dose changes or treatment stops, when appetite may return. Habits support the result. They do not guarantee it.
Waiting too long to slow down when the cut is too aggressive
Momentum makes it hard to slow down when the scale is dropping fast. Picture a man losing 1.5 percent of body weight per week for three weeks while his bench press drops 10 pounds and his squat drops 15. Those numbers do not tell him how much muscle he is losing, since fatigue, under-eating and symptoms can all lower strength. They are a clear sign the plan needs review. A reasonable response is to talk with his clinician about the pace and raise intake around training by an amount they set together. Pushing on because the scale number feels good makes the problem harder to correct later.
24Where to go for the full evidence layer
Read the full evidence on lean-mass protection in how to preserve muscle on GLP-1 medications for every study, every trial number, and every guardrail behind the recommendations here.
Get the drug-specific execution layer from protein targets and training strategy on semaglutide or retatrutide for tighter per-meal protein numbers and session-level nutrition by medication.
Sort the broader peptide landscape using Peptides for Body Recomposition to separate approved obesity drugs from growth hormone secretagogues, collagen, and research-only compounds before making any peptide-related decisions.
Footnotes
Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. (STEP 1)
Back to textBack to text 2Karakasis P, Patoulias D, Fragakis N, Mantzoros CS. Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis. Metabolism. 2025;164:156113. Included 22 randomized trials and 2,258 participants, with lean mass loss comprising approximately 25% of total weight loss. doi:10.1016/j.metabol.2024.156113.
Back to textNeeland IJ, Linge J, Birkenfeld AL. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes Metab. 2024;26(S4):16-27. doi:10.1111/dom.15728.
Back to textBack to text 2Back to text 3Alissou M, et al. Impact of semaglutide on fat mass, lean mass and muscle function in patients with obesity: the SEMALEAN study. Diabetes Obes Metab. 2026. PubMed
Back to textMozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity. 2025. doi:10.1002/oby.24336
Back to textBack to text 2Morton RW, et al. A systematic review, meta-analysis and meta-regression of the effect of protein supplementation on resistance training-induced gains in muscle mass and strength in healthy adults. Br J Sports Med. 2018;52(6):376-384.
Back to textHelms ER, et al. A systematic review of dietary protein during caloric restriction in resistance trained lean athletes: a case for higher intakes. Int J Sport Nutr Exerc Metab. 2014;24(2):127-138.
Back to textJager R, et al. International Society of Sports Nutrition position stand: protein and exercise. J Int Soc Sports Nutr. 2017;14:20.
Back to textLincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. (SELECT)
Back to textJastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. (SURMOUNT-1)
Back to textFrías JP, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. 2025;393(1):26-36. doi:10.1056/NEJMoa2416394. (SURMOUNT-5)
Back to textBack to text 2Garvey WT, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes. Lancet. 2023;402(10402):613-626. (SURMOUNT-2)
Back to textEli Lilly. Lilly's triple agonist retatrutide delivered weight loss of average 71.2 pounds in people with obesity and knee osteoarthritis (TRIUMPH-4). Press release, December 2025, with adverse-event and discontinuation rates for the 12 mg and placebo groups. PDF
Back to textBack to text 2Back to text 3Back to text 4Coskun T, Wu Q, Schloot NC, et al. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. Lancet Diabetes Endocrinol. 2025, 13(8), 674-684, published online 30 June 2025. doi.org/10.1016/S2213-8587(25)00092-0. PubMed 40609566
Back to textBack to text 2Canal de Velasco LM, González Flores JE, Kraus Fischer G, et al. Testosterone replacement therapy as a potential strategy to preserve lean mass in men with persistently low serum testosterone receiving GLP-1 receptor agonists: a narrative review. Cureus. 2026, 18(3), published 23 March 2026. Cureus. PubMed 42037905
Back to textRubino D, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity. JAMA. 2021;325(14):1414-1425. (STEP 4) PubMed
Back to textBack to text 2Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity. JAMA. 2024;331(1):38-48. (SURMOUNT-4)
Back to textBack to text 2US Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss. Content current as of 1 October 2026. FDA. US Food and Drug Administration. Warning letter to GLP-1 Solution, MARCS-CMS 715883. 9 September 2025. FDA. Alliance for Pharmacy Compounding. Retatrutide (and other things that you shouldn't be compounding). April 2025. APC. Lakshmanan I, Griffin G. People are buying unregulated, injectable peptides from Chinese factories. Are they safe? Here & Now, WBUR, 24 March 2026, interview with journalist Ezra Marcus. WBUR
Back to textBack to text 2Back to text 3Back to text 4Feraco A, et al. Obesity medications and precision nutrition: synergistic interventions and integrated approach in obesity management. Curr Obes Rep. 2026;15:13.
Back to textŠantić R, Martinović L, Pavlović N, et al. Lean mass and musculoskeletal preservation in GLP-1-based obesity treatment: nutrition, exercise, supplementation, and monitoring strategies. Metabolites. 2026. PubMed
Back to textUS Food and Drug Administration. Wegovy (semaglutide) prescribing information. 2026. PDF
Back to textBack to text 2US Food and Drug Administration. Zepbound (tirzepatide) prescribing information. 2026. PDF
Back to textBack to text 2Back to text 3Back to text 4World Anti-Doping Agency. 2026 Monitoring Program. September 2025. PDF
Back to textWorld Anti-Doping Agency. 2026 Prohibited List. September 2025. PDF
Back to textEli Lilly. Retatrutide A1C results press release. October 2026. Lilly investor news
Back to textBack to text 2Back to text 3Eli Lilly. TRIUMPH-1 topline results press release, company-reported, including the selected 104-week extension group. May 2026. Lilly investor news
Back to textBack to text 2Back to text 3Eli Lilly. TRIUMPH-2 and TRIUMPH-3 topline results press release, company-reported. July 2026. Lilly investor news
Back to textBack to text 2Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. DOI
Back to textWorld Anti-Doping Agency. Therapeutic Use Exemptions. WADA
Back to textHudson JL, Kim JE, Paddon-Jones D, Campbell WW. Within-day protein distribution does not influence body composition responses during weight loss in resistance-training adults who are overweight. Am J Clin Nutr. 2017;106(5):1190-1196. Both groups ate 90 g protein per day, about 1.0 to 1.1 g/kg. doi:10.3945/ajcn.117.158246. PMC
Back to textBack to text 2Tavares H, Roschel H, Felício V, et al. Effects of daily protein intake frequency during 8 weeks of resistance training on lean mass and strength adaptations: a randomized non-controlled clinical trial. J Sports Med Phys Fitness. 2025;65(10):1337-1345. doi:10.23736/S0022-4707.25.16698-X. PubMed
Back to textBack to text 2US Food and Drug Administration. Mounjaro (tirzepatide) prescribing information, including SURPASS-CVOT results in section 14. 2026. PDF. Supplement approval letter for NDA 215866/S-044 and S-045, signed 27 August 2026. PDF. Trial record NCT04255433
Back to textBhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018, 103(5), 1715-1744. doi.org/10.1210/jc.2018-00229. PubMed 29562364
Back to textCorona G, Rastrelli G, Monami M, et al. Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. Eur J Endocrinol. 2013, 168(6), 829-843. doi.org/10.1530/EJE-12-0955. PubMed 23482592
Back to textUS Department of Agriculture, FoodData Central, SR Legacy entries for roasted chicken breast (FDC 171477), roasted chicken thigh (172388), farmed and wild cooked Atlantic salmon (175168, 171998), cooked Atlantic cod (171956), broiled 93% lean ground beef (174752), raw firm tofu prepared with calcium sulfate (172475), and cooked long-grain white rice (168878). FoodData Central
Back to textTRIUMPH-5, a study of retatrutide compared with tirzepatide in adults with obesity. Trial record NCT06662383. Eli Lilly trial page, enrollment status. Lilly Trials
Back to textBack to text 2Sanyal AJ, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024, 30(7), 2037-2048. The substudy measured blood biomarkers including FIB-4, ELF, K-18 and pro-C3, with no liver biopsy endpoint. Nature Medicine. PubMed 38858523
Back to textCoskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metab. 2022, 34(9), 1234-1247. doi.org/10.1016/j.cmet.2022.07.013. Cell Metabolism PDF
Back to textBack to text 2Back to text 3Back to text 4Corbin KD, Carnero EA, Allerton TD, et al. Glucagon-like peptide-1/glucagon receptor agonism associates with reduced metabolic adaptation and higher fat oxidation: a randomized trial. Obesity. 2023, 31(2), 350-362. Phase 1b, double-blind, placebo-controlled, 19 days, 35 adults with overweight or obesity. doi.org/10.1002/oby.23633. PubMed 36695055
Back to textBack to text 2Back to text 3Back to text 4Bellido V, le Roux CW, Ekinci EI, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet. 2026, 408(10563), 1455-1472. doi.org/10.1016/S0140-6736(26)01861-1. PubMed 42810372
Back to textJastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity, a phase 2 trial. N Engl J Med. 2023, 389(6), 514-526. doi.org/10.1056/NEJMoa2301972. PubMed 37366315
Back to textBack to text 2Smith GI, Julliand S, Reeds DN, et al. Fish oil-derived n-3 PUFA therapy increases muscle mass and function in healthy older adults. Am J Clin Nutr. 2015, 102(1), 115-122. doi.org/10.3945/ajcn.114.105833. PubMed 25994567
Back to textReddit r/Retatrutide. "Thinking of adding Tesa to my stack with Reta and Test." Individual self-report. Reddit
Back to textReddit r/Retatrutide. "What other peptide can you stack with reta?" Individual self-reports and suggestions. Reddit
Back to textReddit r/Retatrutide. "Running heart rate." Individual self-report. Reddit
Back to textReddit r/Retatrutide. "Increased heart rate." Individual self-report. Reddit
Back to textReddit r/Retatrutide. "For those on Retatrutide only, tell us your starting dose and the side effects." Individual self-report in the comments. Reddit
Back to textReddit r/Retatrutide. "2.5 months in, still have nausea and now bad reflux." Individual self-report. Reddit
Back to textReddit r/Retatrutide. "How are you dealing with strength loss on Retatrutide (mentally + physically)?" Individual self-reports in the comments. Reddit
Back to text
